Sacrococcygeal    B-Malignancy114237561
teratoma    I-Malignancy114237561

Imperforate    O
anus    O
is    O
an    O
occasional    O
complication    O
of    O
sacrococcygeal    B-Malignancy114237561
teratoma    I-Malignancy114237561
.    O

Sacrococcygeal    B-Malignancy114237561
teratoma    I-Malignancy114237561
,    O
tumours    O
formed    O
from    O
different    O
types    O
of    O
tissue    O
,    O
that    O
can    O
form    O
,    O
are    O
thought    O
to    O
be    O
related    O
to    O
primitive    O
streak    O
remnants    O
,    O
which    O
ordinarily    O
disappear    O
.    O

Multiple    B-Malignancy114237561
mucosal    I-Malignancy114237561
neuromata    I-Malignancy114237561

Multiple    B-Malignancy114237561
endocrine    I-Malignancy114237561
neoplasia    I-Malignancy114237561
type    I-Malignancy114237561
2b    I-Malignancy114237561

Multiple    B-Malignancy114237561
mucosal    I-Malignancy114237561
neuroma    I-Malignancy114237561
syndrome    I-Malignancy114237561

Early    O
clinical    O
trials    O
indicate    O
that    O
imatinib    O
may    O
be    O
effective    O
in    O
treatment    O
of    O
dermatofibrosarcoma    B-Malignancy114237561
protuberans    I-Malignancy114237561
.    O

Dermatofibrosarcoma    B-Malignancy114237561
protuberans    I-Malignancy114237561

In    O
2003    O
,    O
Menino    O
underwent    O
surgery    O
at    O
Brigham    O
and    O
Women    O
's    O
Hospital    O
to    O
remove    O
a    O
rare    O
sarcoma    O
(    O
DFSP    B-Malignancy114237561
)    O
on    O
his    O
back    O
.    O

Mismatch    B-Malignancy114237561
repair    I-Malignancy114237561
cancer    I-Malignancy114237561
syndrome    I-Malignancy114237561
(    O
MMRCS    O
)    O
is    O
a    O
cancer    O
syndrome    O
associated    O
with    O
biallelic    O
DNA    O
mismatch    O
repair    O
mutations    O
.    O

A    O
number    O
of    O
genetic    O
syndromes    O
are    O
associated    O
with    O
the    O
development    O
of    O
ependymoma    B-Malignancy114237561
,    O
including    O
neurofibromatosis    O
type    O
II    O
(    O
NF2    O
)    O
,    O
Turcot    B-Malignancy114237561
syndrome    I-Malignancy114237561
B    O
,    O
and    O
MEN1    O
syndrome    O
.    O

In    O
addition    O
,    O
in    O
female    O
dogs    O
from    O
ovary    O
remains    O
a    O
granulosa    B-Malignancy114237561
cell    I-Malignancy114237561
tumour    I-Malignancy114237561
with    O
Läufigkeitssymptomen    O
,    O
accretion    O
of    O
the    O
mammary    O
glands    O
,    O
skin    O
problems    O
,    O
bone    O
marrow    O
suppression    O
and    O
endometrial    O
hyperplasia    O
develops    O
.    O

Granulosa    B-Malignancy114237561
cell    I-Malignancy114237561
tumor    I-Malignancy114237561

Ovarian    O
tumors    O
such    O
as    O
granulosa    B-Malignancy114237561
tumor    I-Malignancy114237561
,    O
thecomas    O
,    O
Sertoli–Leydig    B-Malignancy114237561
cell    I-Malignancy114237561
tumor    I-Malignancy114237561
(    O
androblastomas    O
)    O
,    O
and    O
gynandroblastomas    O
,    O
as    O
well    O
as    O
ovarian    O
cancer    O
.    O

In    O
addition    O
,    O
serum    O
levels    O
of    O
inhibin    O
have    O
been    O
shown    O
to    O
reflect    O
the    O
size    O
of    O
granulosa-cell    B-Malignancy114237561
tumors    I-Malignancy114237561
and    O
can    O
therefore    O
be    O
used    O
as    O
a    O
marker    O
for    O
primary    O
as    O
well    O
as    O
recurrent    O
disease    O
.    O

In    O
other    O
polyomaviruses    O
,    O
such    O
as    O
Merkel    O
cell    O
polyomavirus    O
,    O
which    O
causes    O
Merkel    B-Malignancy114237561
cell    I-Malignancy114237561
carcinoma    I-Malignancy114237561
in    O
humans    O
,    O
STag    O
appears    O
to    O
be    O
important    O
for    O
replication    O
and    O
to    O
be    O
an    O
oncoprotein    O
in    O
its    O
own    O
right    O
.    O

Merkel    O
cell    O
polyomavirus    O
(    O
MCPyV    O
)    O
is    O
a    O
virus    O
causally    O
associated    O
with    O
a    O
rare    O
and    O
aggressive    O
human    O
skin    O
cancer    O
called    O
Merkel    B-Malignancy114237561
cell    I-Malignancy114237561
carcinoma    I-Malignancy114237561
.    O

David    O
Brudnoy    O
,    O
64    O
,    O
American    O
radio    O
talk    O
show    O
host    O
(    O
Boston    O
)    O
,    O
Merkel    B-Malignancy114237561
cell    I-Malignancy114237561
carcinoma    I-Malignancy114237561
.    O

He    O
died    O
a    O
little    O
over    O
a    O
month    O
later    O
from    O
a    O
rare    O
form    O
of    O
skin    O
cancer    O
(    O
Merkel    B-Malignancy114237561
cell    I-Malignancy114237561
carcinoma    I-Malignancy114237561
)    O
on    O
September    O
11    O
,    O
2007    O
.    O

It    O
has    O
been    O
used    O
in    O
miR    O
fluorescence    O
in    O
situ    O
hybridization    O
to    O
distinguish    O
Merkel    O
cell    O
polyomavirus    O
-    O
positive    O
Merkel    B-Malignancy114237561
cell    I-Malignancy114237561
carcinoma    I-Malignancy114237561
from    O
other    O
common    O
skin    O
cancers    O
.    O

His    O
clinical    O
interests    O
are    O
in    O
developing    O
more    O
effective    O
treatments    O
for    O
advanced    O
stages    O
of    O
melanoma    O
and    O
non    O
-    O
melanoma    O
skin    O
cancers    O
(    O
such    O
as    O
Merkel    B-Malignancy114237561
Cell    I-Malignancy114237561
Carcinoma    I-Malignancy114237561
)    O
,    O
and    O
renal    B-Malignancy114237561
cancer    I-Malignancy114237561
.    O

Avelumab    O
has    O
been    O
FDA    O
approved    O
for    O
the    O
treatment    O
of    O
Merkel-cell    B-Malignancy114237561
carcinoma    I-Malignancy114237561
and    O
Phase    O
III    O
trials    O
have    O
been    O
reached    O
for    O
this    O
drug    O
in    O
the    O
treatment    O
of    O
non    O
-    O
small    O
cell    O
lung    O
cancer    O
.    O

His    O
name    O
was    O
attached    O
to    O
the    O
eponymous    O
Ebstein    O
's    O
anomaly    O
(    O
a    O
rare    O
congenital    O
heart    O
defect    O
)    O
and    O
Pel-Ebstein    B-Malignancy114237561
fever    I-Malignancy114237561
(    O
a    O
remittent    O
fever    O
associated    O
with    O
Hodgkin's    B-Malignancy114237561
disease    I-Malignancy114237561
)    O
.    O

Pleuropulmonary    B-Malignancy114237561
blastoma    I-Malignancy114237561

Pleuropulmonary    B-Malignancy114237561
blastoma    I-Malignancy114237561
,    O
a    O
type    O
of    O
lung    O
cancer    O

Pediatric    B-Malignancy114237561
ependymomas    I-Malignancy114237561
are    O
similar    O
in    O
nature    O
to    O
the    O
adult    O
form    O
of    O
ependymoma    B-Malignancy114237561
in    O
that    O
they    O
are    O
thought    O
to    O
arise    O
from    O
radial    O
glial    O
cells    O
lining    O
the    O
ventricular    O
system    O
.    O

Thakker    O
's    O
research    O
investigates    O
neuroendocrine    O
tumours    O
such    O
as    O
multiple    B-Malignancy114237561
endocrine    I-Malignancy114237561
neoplasia    I-Malignancy114237561
type    I-Malignancy114237561
1    I-Malignancy114237561
(MEN1)    I-Malignancy114237561
and    O
the    O
molecular    O
basis    O
of    O
disorders    O
of    O
calcium    O
homeostasis    O
.    O

M13    O
phage    O
-    O
malformation    O
-    O
mapping    O
-    O
marker    O
-    O
melanoma    O
-    O
melting    O
-    O
Johann    O
Mendel    O
-    O
Mendelian    O
inheritance    O
-    O
message    O
-    O
messenger    O
RNA    O
-    O
metaphase    O
-    O
microarray    O
technology    O
-    O
microsatellite    O
-    O
missense    O
mutation    O
-    O
mitochondrial    O
DNA    O
-    O
mobility    O
shift    O
-    O
molecular    O
weight    O
size    O
marker    O
-    O
monoclonal    O
antibody    O
-    O
monosomy    O
-    O
mouse    O
model    O
-    O
mRNA    O
-    O
multicistronic    O
message    O
-    O
multicopy    O
plasmid    O
-    O
multiple    O
cloning    O
site    O
-    O
multiple    B-Malignancy114237561
endocrine    I-Malignancy114237561
neoplasia,    I-Malignancy114237561
type    I-Malignancy114237561
1    I-Malignancy114237561
-    O
mutation    O
-    O

Adenomas    O
of    O
the    O
anterior    O
pituitary    O
gland    O
are    O
a    O
major    O
clinical    O
feature    O
of    O
multiple    B-Malignancy114237561
endocrine    I-Malignancy114237561
neoplasia    I-Malignancy114237561
type    I-Malignancy114237561
1    I-Malignancy114237561
(    O
MEN1    O
)    O
,    O
a    O
rare    O
inherited    O
endocrine    O
syndrome    O
that    O
affects    O
1    O
person    O
in    O
every    O
30,000    O
.    O

Menin    O
is    O
a    O
putative    O
tumor    O
suppressor    O
associated    O
with    O
multiple    B-Malignancy114237561
endocrine    I-Malignancy114237561
neoplasia    I-Malignancy114237561
type    I-Malignancy114237561
1    I-Malignancy114237561
(    O
MEN-1    O
syndrome    O
)    O
.    O

Familial    O
loss    O
of    O
one    O
copy    O
of    O
MEN1    O
is    O
seen    O
In    O
association    O
with    O
MEN-1    B-Malignancy114237561
syndrome    I-Malignancy114237561
.    O

Three    O
case    O
reports    O
have    O
found    O
that    O
chromosome    O
translocations    O
between    O
"    O
FIP1L1    O
"    O
and    O
"    O
RARA    O
"    O
gene    O
loci    O
are    O
associated    O
with    O
two    O
cases    O
of    O
acute    O
promyelocytic    O
leukemia    O
and    O
one    O
case    O
of    O
juvenile    B-Malignancy114237561
myelomonocytic    I-Malignancy114237561
leukemia    I-Malignancy114237561
.    O

Juvenile    B-Malignancy114237561
myelomonocytic    I-Malignancy114237561
leukemia    I-Malignancy114237561

Multiple    B-Malignancy114237561
endocrine    I-Malignancy114237561
neoplasia    I-Malignancy114237561

Paragangliomas    O
may    O
also    O
occur    O
in    O
MEN    B-Malignancy114237561
type    O
2A    O
and    O
2B.    O
They    O
are    O
seen    O
in    O
at    O
a    O
higher    O
incidence    O
in    O
people    O
living    O
at    O
high    O
altitude    O
.    O

Such    O
co    O
-    O
occurrences    O
are    O
usually    O
seen    O
in    O
patients    O
carrying    O
hereditary    O
syndromes    O
like    O
multiple    B-Malignancy114237561
endocrine    I-Malignancy114237561
neoplasia    I-Malignancy114237561
(    O
MEN    O
)    O
,    O
neurofibromatosis    O
1    O
(    O
NF1    O
)    O
,    O
or    O
von    B-Malignancy114237561
Hippel-Lindau    I-Malignancy114237561
(    O
VHL    O
)    O
disease    O
.    O

multiple    B-Malignancy114237561
endocrine    I-Malignancy114237561
neoplasia    I-Malignancy114237561
type    O
I    O
,    O

In    O
July    O
2013    O
,    O
the    O
former    O
Mediacorp    O
artiste    O
was    O
diagnosed    O
with    O
multiple    B-Malignancy114237561
endocrine    I-Malignancy114237561
neoplasia    I-Malignancy114237561
(MEN)    I-Malignancy114237561
syndrome    I-Malignancy114237561
,    O
and    O
was    O
later    O
confirmed    O
to    O
have    O
Neuroendocrine    O
cancer    O
tumors    O
in    O
her    O
liver    O
.    O

Minimally    B-Malignancy114237561
invasive    I-Malignancy114237561
adenocarcinoma    I-Malignancy114237561
of    I-Malignancy114237561
the    I-Malignancy114237561
lung    I-Malignancy114237561

Heart    B-Malignancy114237561
cancer    I-Malignancy114237561

Heart    B-Malignancy114237561
cancer    I-Malignancy114237561
–    O
Cancer    O
of    O
the    O
heart    O
is    O
very    O
rare    O
and    O
those    O
cancers    O
tend    O
to    O
be    O
benign    O
.    O

CTVT    B-Malignancy114237561
–    O
(    O
i    O
)    O
Canine    B-Malignancy114237561
Transmissible    I-Malignancy114237561
Venereal    I-Malignancy114237561
Tumour    I-Malignancy114237561

Canine    B-Malignancy114237561
transmissible    I-Malignancy114237561
venereal    I-Malignancy114237561
tumors    I-Malignancy114237561
(    O
CTVTs    O
)    O
,    O
also    O
called    O
transmissible    B-Malignancy114237561
venereal    I-Malignancy114237561
tumors    I-Malignancy114237561
(    O
TVTs    O
)    O
,    O
canine    B-Malignancy114237561
transmissible    I-Malignancy114237561
venereal    I-Malignancy114237561
sarcoma    I-Malignancy114237561
(    O
CTVS    O
)    O
,    O
sticker    B-Malignancy114237561
tumors    I-Malignancy114237561
and    O
infectious    B-Malignancy114237561
sarcoma    I-Malignancy114237561
is    O
a    O
histiocytic    O
tumor    O
of    O
the    O
external    O
genitalia    O
of    O
the    O
dog    O
and    O
other    O
canines    O
,    O
and    O
is    O
transmitted    O
from    O
animal    O
to    O
animal    O
during    O
mating    O
.    O

Cronkite-Canada    B-Malignancy114237561
syndrome    I-Malignancy114237561

:    O
Ganglioneuroma    O
,    O
Neuroblastoma    O
,    O
Atypical    B-Malignancy114237561
teratoid    I-Malignancy114237561
rhabdoid    I-Malignancy114237561
tumor    I-Malignancy114237561
,    O
Retinoblastoma    O
,    O
Esthesioneuroblastoma    B-Malignancy114237561

Esthesioneuroblastoma    B-Malignancy114237561
,    O
also    O
known    O
as    O
olfactory    O
neuroblastoma    O
,    O
is    O
believed    O
to    O
arise    O
from    O
the    O
olfactory    O
epithelium    O
and    O
its    O
classification    O
remains    O
controversial    O
.    O

Recurrence    O
with    O
malignant    O
endodermal    B-Malignancy114237561
sinus    I-Malignancy114237561
tumor    I-Malignancy114237561
has    O
been    O
reported    O
in    O
cases    O
of    O
formerly    O
benign    O
mature    O
teratoma    O
,    O
even    O
in    O
fetiform    O
teratoma    O
and    O
fetus    O
in    O
fetu    O
.    O

These    O
cells    O
can    O
develop    O
into    O
a    O
frankly    O
malignant    O
tumor    O
known    O
as    O
yolk    B-Malignancy114237561
sac    I-Malignancy114237561
tumor    I-Malignancy114237561
or    O
endodermal    B-Malignancy114237561
sinus    I-Malignancy114237561
tumor    I-Malignancy114237561
.    O

Endodermal    B-Malignancy114237561
sinus    I-Malignancy114237561
tumor    I-Malignancy114237561
,    O
a    O
cancer    O
of    O
the    O
germ    O
cell    O
tumor    O
group    O

Other    O
less    O
common    O
liver    O
cancers    O
include    O
carcinosarcomas    O
,    O
teratoma    B-Malignancy114237561
,    O
yolk    B-Malignancy114237561
sac    I-Malignancy114237561
tumour    I-Malignancy114237561
,    O
carcinoid    O
tumours    O
and    O
lymphomas    O
.    O

In    O
2005    O
,    O
Hazlewood    O
was    O
diagnosed    O
with    O
terminal    O
renal    B-Malignancy114237561
cancer    I-Malignancy114237561
,    O
and    O
he    O
undertook    O
an    O
extensive    O
round    O
of    O
interviews    O
and    O
promotional    O
activities    O
in    O
support    O
of    O
his    O
last    O
album    O
,    O
"    O
Cake    O
or    O
Death    O
"    O
.    O

He    O
died    O
from    O
kidney    B-Malignancy114237561
cancer    I-Malignancy114237561
in    O
1965    O
in    O
Vienna    O
,    O
and    O
is    O
buried    O
in    O
an    O
Ehrengrab    O
at    O
the    O
Zentralfriedhof    O
.    O

In    O
2007    O
,    O
Joseph    O
Russo    O
died    O
of    O
kidney    B-Malignancy114237561
cancer    I-Malignancy114237561
in    O
prison    O
.    O

In    O
July    O
2002    O
,    O
Owen    O
was    O
diagnosed    O
with    O
kidney    B-Malignancy114237561
cancer    I-Malignancy114237561
,    O
and    O
he    O
became    O
an    O
Honorary    O
Patron    O
of    O
Kidney    O
Cancer    O
UK    O
in    O
2003    O
.    O

Kidney    B-Malignancy114237561
cancer    I-Malignancy114237561
(    O
including    O
renal    O
cell    O
carcinoma    O
)    O

In    O
the    O
case    O
of    O
uranium    O
mill    O
workers    O
and    O
ore    O
transporters    O
,    O
renal    B-Malignancy114237561
cancer    I-Malignancy114237561
and    O
chronic    O
renal    O
disease    O
are    O
also    O
compensable    O
conditions    O
.    O

He    O
returned    O
,    O
filling    O
in    O
for    O
James    O
Whale    O
during    O
James    O
's    O
battle    O
with    O
kidney    B-Malignancy114237561
cancer    I-Malignancy114237561
.    O

Kidney    B-Malignancy114237561
cancer    I-Malignancy114237561
:    O
uses    O
TNM    O
.    O

John    O
Jennings    O
was    O
diagnosed    O
with    O
metastatic    O
kidney    B-Malignancy114237561
cancer    I-Malignancy114237561
in    O
March    O
2014    O
.    O

Eventually    O
,    O
Dot    O
informed    O
Den    O
that    O
she    O
was    O
dying    O
and    O
he    O
was    O
shocked    O
to    O
hear    O
that    O
she    O
had    O
kidney    B-Malignancy114237561
cancer    I-Malignancy114237561
.    O

Walaker    O
died    O
on    O
December    O
2    O
,    O
2014    O
at    O
the    O
age    O
of    O
73    O
,    O
from    O
kidney    B-Malignancy114237561
cancer    I-Malignancy114237561
.    O

Renal    B-Malignancy114237561
cancer    I-Malignancy114237561
:    O
Patients    O
with    O
renal    O
cell    O
carcinoma    O
(    O
RCC    O
)    O
exhibited    O
a    O
significantly    O
high    O
amount    O
of    O
Mycoplasma    O
sp    O
.    O
compared    O
with    O
the    O
healthy    O
control    O
group    O
.    O

Cake    O
or    O
Death    O
,    O
the    O
final    O
album    O
by    O
idiosyncratic    O
singer    O
-    O
songwriter    O
-    O
producer    O
Lee    O
Hazlewood    O
,    O
was    O
released    O
November    O
27    O
,    O
2006    O
,    O
after    O
he    O
received    O
a    O
diagnosis    O
of    O
terminal    O
renal    B-Malignancy114237561
cancer    I-Malignancy114237561
in    O
2005    O
.    O

On    O
March    O
27    O
,    O
2009    O
,    O
her    O
husband    O
,    O
Fred    O
Holliday    O
II    O
,    O
was    O
diagnosed    O
with    O
metastatic    O
kidney    B-Malignancy114237561
cancer    I-Malignancy114237561
,    O
after    O
months    O
of    O
escalating    O
pain    O
medication    O
prescribed    O
for    O
symptom    O
relief    O
,    O
without    O
a    O
diagnosis    O
of    O
the    O
cause    O
of    O
the    O
pain    O
.    O

They    O
remained    O
together    O
until    O
his    O
death    O
of    O
kidney    B-Malignancy114237561
cancer    I-Malignancy114237561
on    O
30    O
March    O
2005    O
.    O

Most    O
renal    O
cell    O
carcinoma    O
,    O
the    O
most    O
common    O
form    O
of    O
kidney    B-Malignancy114237561
cancer    I-Malignancy114237561
,    O
arises    O
from    O
the    O
convoluted    O
tubules    O
.    O

His    O
clinical    O
interests    O
are    O
in    O
developing    O
more    O
effective    O
treatments    O
for    O
advanced    O
stages    O
of    O
melanoma    O
and    O
non    O
-    O
melanoma    O
skin    O
cancers    O
(    O
such    O
as    O
Merkel    B-Malignancy114237561
Cell    I-Malignancy114237561
Carcinoma    I-Malignancy114237561
)    O
,    O
and    O
renal    B-Malignancy114237561
cancer    I-Malignancy114237561
.    O

Still    O
working    O
until    O
the    O
end    O
of    O
his    O
life    O
,    O
Jack    O
Newfield    O
died    O
in    O
New    O
York    O
City    O
,    O
succumbing    O
to    O
kidney    B-Malignancy114237561
cancer    I-Malignancy114237561
on    O
December    O
21    O
,    O
2004    O
,    O
at    O
the    O
age    O
of    O
66    O
.    O

He    O
died    O
April    O
29    O
,    O
2015    O
,    O
aged    O
84    O
,    O
of    O
complications    O
of    O
renal    B-Malignancy114237561
cancer    I-Malignancy114237561
in    O
Evanston    O
,    O
Illinois    O
in    O
his    O
home    O
.    O

He    O
died    O
on    O
April    O
27    O
,    O
2015    O
of    O
kidney    B-Malignancy114237561
cancer    I-Malignancy114237561
.    O

Bob    O
is    O
horrified    O
to    O
learn    O
that    O
he    O
has    O
been    O
diagnosed    O
with    O
a    O
terminal    O
form    O
of    O
kidney    B-Malignancy114237561
cancer    I-Malignancy114237561
and    O
might    O
not    O
live    O
to    O
see    O
their    O
baby    O
born    O
.    O

Clear    B-Malignancy114237561
cell    I-Malignancy114237561
sarcoma    I-Malignancy114237561
of    I-Malignancy114237561
the    I-Malignancy114237561
kidney    I-Malignancy114237561
(    O
CCSK    O
)    O
is    O
an    O
extremely    O
rare    O
type    O
of    O
kidney    B-Malignancy114237561
cancer    I-Malignancy114237561
comprising    O
3%    O
of    O
all    O
pediatric    O
renal    O
tumours    O
.    O

The    O
former    O
ozeki    O
Hokutenyu    O
,    O
head    O
coach    O
of    O
the    O
Hatachiyama    O
stable    O
,    O
dies    O
of    O
cancer    B-Malignancy114237561
of    I-Malignancy114237561
the    I-Malignancy114237561
kidney    I-Malignancy114237561
aged    O
45    O
.    O

Carcelle    O
died    O
from    O
kidney    B-Malignancy114237561
cancer    I-Malignancy114237561
on    O
31    O
August    O
2014    O
in    O
Paris    O
.    O

Frequently    O
,    O
the    O
site    O
of    O
origin    O
is    O
the    O
gastrointestinal    O
tract    O
,    O
since    O
the    O
liver    O
is    O
close    O
to    O
many    O
of    O
these    O
metabolically    O
active    O
,    O
blood    O
-    O
rich    O
organs    O
near    O
to    O
blood    O
vessels    O
and    O
lymph    O
nodes    O
(    O
such    O
as    O
pancreatic    O
cancer    O
,    O
stomach    O
cancer    O
,    O
colon    O
cancer    O
and    O
carcinoid    O
tumors    O
mainly    O
of    O
the    O
appendix    O
)    O
,    O
but    O
also    O
from    O
breast    O
cancer    O
,    O
ovarian    O
cancer    O
,    O
lung    O
cancer    O
,    O
renal    B-Malignancy114237561
cancer    I-Malignancy114237561
,    O
prostate    O
cancer    O
.    O

Wakanohana    O
Kanji    O
I    O
,    O
82    O
,    O
Japanese    O
sumo    O
wrestler    O
,    O
kidney    B-Malignancy114237561
cancer    I-Malignancy114237561
.    O

In    O
addition    O
to    O
Wilms    O
tumor    O
and    O
hepatoblastoma    O
,    O
children    O
with    O
BWS    O
have    O
been    O
shown    O
in    O
individual    O
case    O
reports    O
to    O
develop    O
ganglioneuroma    O
,    O
adrenocortical    B-Malignancy114237561
carcinoma    I-Malignancy114237561
,    O
acute    O
lymphoid    O
leukemia    O
,    O
liver    O
sarcoma    O
,    O
thyroid    O
carcinoma    O
,    O
melanoma    O
,    O
rhabdomyosarcoma    O
,    O
and    O
mesoblastic    O
nephroma    O
.    O

adrenalectomy    O
,    O
i.e.    O
surgical    O
removal    O
of    O
the    O
adrenal    O
gland    O
is    O
done    O
in    O
conditions    O
like    O
Conn    O
syndrome    O
,    O
pheochromocytoma    O
,    O
adreno-cortical    B-Malignancy114237561
cancer    I-Malignancy114237561
etc    O
.    O

Adrenal    O
gland    O
tumors    O
,    O
adrenocortical    O
adenomas    O
,    O
and    O
adrenocortical    B-Malignancy114237561
carcinoma    I-Malignancy114237561
,    O
as    O
well    O
as    O
adrenal    O
hyperplasia    O
due    O
to    O
pituitary    O
adenomas    O
(    O
as    O
in    O
Cushing    O
's    O
syndrome    O
)    O
.    O

Mir-210    O
has    O
been    O
suggested    O
as    O
a    O
useful    O
biomarker    O
to    O
distinguish    O
adrenocortical    B-Malignancy114237561
carcinoma    I-Malignancy114237561
from    O
adrenocortical    O
adenoma    O
.    O

Adrenal    B-Malignancy114237561
carcinoma    I-Malignancy114237561
are    O
very    O
rare    O
,    O
with    O
an    O
incidence    O
of    O
1    O
case    O
per    O
million    O
per    O
year    O
.    O

Plasma    B-Malignancy114237561
cell    I-Malignancy114237561
leukemia    I-Malignancy114237561
,    O
an    O
aggressive    O
form    O
of    O
MM    O

On    O
April    O
22    O
,    O
1998    O
,    O
Worth    O
died    O
of    O
bronchioloalveolar    B-Malignancy114237561
carcinoma    I-Malignancy114237561
,    O
a    O
form    O
of    O
lung    O
cancer    O
,    O
in    O
Los    O
Angeles    O
.    O

Microscopically    O
,    O
the    O
neoplastic    O
epithelial    O
cells    O
tend    O
to    O
grow    O
along    O
the    O
alveolar    O
walls    O
,    O
in    O
a    O
fashion    O
similar    O
to    O
the    O
mucinous    O
variant    O
of    O
bronchioloalveolar    B-Malignancy114237561
carcinoma    I-Malignancy114237561
,    O
a    O
more    O
common    O
form    O
of    O
adenocarcinoma    O
.    O

Differential    O
diagnosis    O
of    O
MCACL    O
includes    O
secondary    O
metastatic    O
cystadenocarcinomatous    O
lesions    O
,    O
particularly    O
from    O
the    O
pancreas    O
or    O
ovary    O
,    O
mucoepidermoid    O
carcinoma    O
,    O
and    O
pulmonary    O
mucinous    O
bronchioloalveolar    B-Malignancy114237561
carcinoma    I-Malignancy114237561
.    O

:    O
:    O
1.1.3    O
Pleomorphic    B-Malignancy114237561
xanthoastrocytoma    I-Malignancy114237561
(    O
ICD    O
-    O
O    O
9424/3    O
,    O
WHO    O
grade    O
II    O
)    O

Mast    B-Malignancy114237561
cell    I-Malignancy114237561
leukemia    I-Malignancy114237561

Testicular    O
cancer    O
,    O
Leydig    B-Malignancy114237561
cell    I-Malignancy114237561
tumour    I-Malignancy114237561
and    O
Sertoli    B-Malignancy114237561
cell    I-Malignancy114237561
tumour    I-Malignancy114237561
are    O
also    O
associated    O
with    O
reduced    O
sperm    O
count    O
and    O
quality    O
.    O

Due    O
to    O
the    O
induction    O
of    O
chronic    O
overproduction    O
of    O
and    O
testosterone    O
,    O
there    O
was    O
concern    O
that    O
long    O
-    O
term    O
bicalutamide    O
monotherapy    O
might    O
induce    O
Leydig    O
cell    O
hyperplasia    O
and    O
tumor    B-Malignancy114237561
(    O
usually    O
benign    O
)    O
,    O
but    O
the    O
evidence    O
indicates    O
that    O
Leydig    O
cell    O
hyperplasia    O
does    O
not    O
occur    O
to    O
a    O
significant    O
extent    O
.    O

Gigantiform    B-Malignancy114237561
cementoma    I-Malignancy114237561
•    O

In    O
1995    O
,    O
at    O
the    O
age    O
of    O
seven    O
,    O
daughter    O
Michelle    O
was    O
diagnosed    O
with    O
adrenal    B-Malignancy114237561
cortical    I-Malignancy114237561
carcinoma    I-Malignancy114237561
,    O
a    O
condition    O
traced    O
to    O
a    O
genetic    O
tendency    O
called    O
Li-Fraumeni    B-Malignancy114237561
syndrome    I-Malignancy114237561
;    O
after    O
painful    O
and    O
intensive    O
treatment    O
she    O
died    O
in    O
December    O
1996    O
.    O

Five    O
months    O
later    O
Sondra    O
herself    O
was    O
also    O
diagnosed    O
with    O
a    O
genetic    O
form    O
of    O
cancer    O
,    O
also    O
linked    O
to    O
Li-Fraumeni    B-Malignancy114237561
syndrome    I-Malignancy114237561
.    O

The    O
main    O
hereditary    O
predispositions    O
are    O
mainly    O
neurofibromatosis    O
type    O
I    O
,    O
Li-Fraumeni    B-Malignancy114237561
syndrome    I-Malignancy114237561
,    O
hereditary    B-Malignancy114237561
nonpolyposis    I-Malignancy114237561
colorectal    I-Malignancy114237561
cancer    I-Malignancy114237561
and    O
tuberous    O
sclerosis    O
.    O

Factors    O
that    O
increase    O
the    O
likelihood    O
of    O
this    O
cancer    O
include    O
Li-Fraumeni    B-Malignancy114237561
syndrome    I-Malignancy114237561
,    O
type    O
one    O
Neurofibromatosis    O
,    O
Beckwith    O
-    O
Wiedemann    O
syndrome    O
,    O
Costello    O
syndrome    O
,    O
and    O
Noonan    O
syndrome    O
.    O

Li-Fraumeni    B-Malignancy114237561
syndrome    I-Malignancy114237561

It    O
may    O
be    O
caused    O
by    O
carney    B-Malignancy114237561
complex    I-Malignancy114237561
,    O
LEOPARD    O
syndrome    O
or    O
Peutz–Jeghers    B-Malignancy114237561
syndrome    I-Malignancy114237561
.    O

Carney    B-Malignancy114237561
complex    I-Malignancy114237561
(    O
CNC    O
)    O
,    O
also    O
known    O
as    O
LAMB    O
syndrome    O
and    O
NAME    O
syndrome    O
is    O
an    O
autosomal    O
dominant    O
condition    O
comprising    O
myxomas    O
of    O
the    O
heart    O
and    O
skin    O
,    O
hyperpigmentation    O
of    O
the    O
skin    O
(    O
lentiginosis    O
)    O
,    O
and    O
endocrine    O
overactivity    O
and    O
is    O
distinct    O
from    O
Carney    O
's    O
triad    O
.    O

Familial    O
isolated    O
pituitary    O
adenoma    O
(    O
FIPA    O
)    O
is    O
a    O
term    O
that    O
used    O
to    O
identify    O
a    O
condition    O
that    O
displays    O
an    O
autosomal    O
dominant    O
inheritance    O
and    O
is    O
characterised    O
by    O
the    O
presence    O
of    O
two    O
or    O
more    O
related    O
patients    O
affected    O
by    O
adenomas    O
of    O
the    O
pituitary    O
gland    O
only    O
,    O
with    O
no    O
other    O
associated    O
symptoms    O
that    O
occur    O
in    O
Multiple    O
endocrine    O
neoplasia    O
Type    O
1    O
or    O
Carney    B-Malignancy114237561
complex    I-Malignancy114237561
.    O

It    O
is    O
a    O
benign    O
tumor    O
most    O
commonly    O
found    O
in    O
the    O
left    O
atrium    O
and    O
can    O
be    O
associated    O
with    O
Carney    B-Malignancy114237561
syndrome    I-Malignancy114237561
.    O

Clear    B-Malignancy114237561
cell    I-Malignancy114237561
sarcoma    I-Malignancy114237561
of    I-Malignancy114237561
the    I-Malignancy114237561
kidney    I-Malignancy114237561
,    O
which    O
is    O
responsible    O
for    O
5    O
-    O
10%    O
of    O
childhood    O
pediatric    O
tumors    O
,    O
occurs    O
predominantly    O
in    O
children    O
from    O
2    O
to    O
3    O
years    O
of    O
age    O
.    O

McGhee    O
died    O
from    O
male    B-Malignancy114237561
breast    I-Malignancy114237561
cancer    I-Malignancy114237561
,    O
aged    O
76    O
.    O

There    O
were    O
also    O
rumours    O
,    O
whose    O
accuracy    O
and    O
substantiation    O
have    O
been    O
questioned    O
,    O
that    O
he    O
had    O
been    O
diagnosed    O
with    O
male    B-Malignancy114237561
breast    I-Malignancy114237561
cancer    I-Malignancy114237561
.    O

Lois    O
finds    O
a    O
lump    O
on    O
Peter    O
's    O
chest    O
and    O
worries    O
that    O
the    O
lump    O
could    O
mean    O
cancer    B-Malignancy114237561
,    O
prompting    O
Peter    O
to    O
see    O
a    O
doctor    O
.    O

Jeghers    O
syndrome    O
due    O
to    O
mutations    O
in    O
the    O
"    O
STK11    O
"    O
tumor    O
suppressor    O
gene    O
(    O
very    O
rare    O
,    O
but    O
a    O
very    O
strong    O
risk    O
factor    O
)    O
;    O
dysplastic    O
nevus    O
syndrome    O
(    O
or    O
familial    O
atypical    O
multiple    O
mole    O
and    O
melanoma    O
syndrome    O
,    O
FAMMM    O
-    O
PC    O
)    O
due    O
to    O
mutations    O
in    O
the    O
"    O
CDKN2A    O
"    O
tumor    O
suppressor    O
gene    O
;    O
autosomal    O
recessive    O
ataxia    O
-    O
telangiectasia    O
and    O
autosomal    O
dominantly    O
inherited    O
mutations    O
in    O
the    O
"    O
BRCA2    O
"    O
gene    O
and    O
"    O
PALB2    O
"    O
gene    O
;    O
hereditary    B-Malignancy114237561
non-polyposis    I-Malignancy114237561
colon    I-Malignancy114237561
cancer    I-Malignancy114237561
(    O
Lynch    O
syndrome    O
)    O
;    O
and    O
familial    B-Malignancy114237561
adenomatous    I-Malignancy114237561
polyposis    I-Malignancy114237561
.    O

Familial    B-Malignancy114237561
adenomatous    I-Malignancy114237561
polyposis    I-Malignancy114237561
(    O
FAP    B-Malignancy114237561
)    O
is    O
an    O
inherited    O
condition    O
in    O
which    O
numerous    O
adenomatous    O
polyps    O
form    O
mainly    O
in    O
the    O
epithelium    O
of    O
the    O
large    O
intestine    O
.    O

Three    O
variants    O
are    O
known    O
to    O
exist    O
,    O
FAP    O
and    O
attenuated    B-Malignancy114237561
FAP    I-Malignancy114237561
(    O
originally    O
called    O
hereditary    B-Malignancy114237561
flat    I-Malignancy114237561
adenoma    I-Malignancy114237561
syndrome    I-Malignancy114237561
)    O
are    O
caused    O
by    O
APC    O
gene    O
defects    O
on    O
chromosome    O
5    O
while    O
autosomal    B-Malignancy114237561
recessive    I-Malignancy114237561
FAP    I-Malignancy114237561
(    O
or    O
MYH-associated    B-Malignancy114237561
polyposis    I-Malignancy114237561
)    O
is    O
caused    O
by    O
defects    O
in    O
the    O
"    O
MUTYH    O
"    O
gene    O
on    O
chromosome    O
1    O
.    O

Diseases    O
of    O
the    O
large    O
intestine    O
which    O
may    O
require    O
surgical    O
removal    O
include    O
Crohn    O
's    O
disease    O
,    O
ulcerative    O
colitis    O
,    O
familial    B-Malignancy114237561
adenomatous    I-Malignancy114237561
polyposis    I-Malignancy114237561
,    O
and    O
total    O
colonic    O
Hirschsprung    O
's    O
disease    O
.    O

Familial    B-Malignancy114237561
adenomatous    I-Malignancy114237561
polyposis    I-Malignancy114237561

The    O
FDA    O
has    O
approved    O
Celebrex    O
for    O
treatment    O
of    O
familial    B-Malignancy114237561
adenomatous    I-Malignancy114237561
polyposis    I-Malignancy114237561
(    O
FAP    O
)    O
.    O

COX-2    O
inhibitor    O
may    O
decrease    O
the    O
rate    O
of    O
polyp    O
formation    O
in    O
people    O
with    O
familial    B-Malignancy114237561
adenomatous    I-Malignancy114237561
polyposis    I-Malignancy114237561
however    O
are    O
associated    O
with    O
the    O
same    O
adverse    O
effects    O
as    O
NSAIDs    O
.    O

This    O
gene    O
is    O
also    O
mutant    O
in    O
familial    B-Malignancy114237561
adenomatous    I-Malignancy114237561
polyposis    I-Malignancy114237561
(    O
FAP    O
)    O
,    O
a    O
more    O
common    O
disease    O
that    O
also    O
predisposes    O
to    O
colon    O
cancer    O
.    O

Increased    O
risk    O
of    O
liver    O
cancer    O
in    O
children    O
can    O
be    O
caused    O
by    O
Beckwith    O
-    O
Wiedemann    O
Syndrome    O
(    O
associated    O
with    O
hepatoblastoma    O
)    O
,    O
familial    B-Malignancy114237561
adenomatous    I-Malignancy114237561
polyposis    I-Malignancy114237561
(    O
associated    O
with    O
hepatoblastoma    O
)    O
,    O
low    O
birth    O
weight    O
(    O
associated    O
with    O
hepatoblastoma    O
)    O
,    O
Progressive    O
familial    O
intrahepatic    O
cholestasis    O
(    O
associated    O
with    O
HCC    O
)    O
and    O
Trisomy    O
18    O
(    O
associated    O
with    O
hepatoblastoma    O
)    O
.    O

These    O
tumors    O
were    O
tested    O
immunohistochemically    O
with    O
a    O
profile    O
similar    O
to    O
that    O
of    O
a    O
choroid    B-Malignancy114237561
plexus    I-Malignancy114237561
tumor    I-Malignancy114237561
;    O
however    O
,    O
morphologically    O
the    O
tumors    O
appeared    O
to    O
be    O
less    O
differentiated    O
than    O
a    O
choroid    O
plexus    O
papilloma    O
and    O
more    O
differentiated    O
than    O
a    O
choroid    O
plexus    O
carcinoma    O
.    O

Inactivating    O
mutations    O
in    O
SMARCB1    O
,    O
formerly    O
known    O
as    O
hSNF5/INI1    O
and    O
a    O
component    O
of    O
the    O
human    O
SWI    O
/    O
SNF    O
remodeling    O
complex    O
have    O
been    O
found    O
in    O
large    O
number    O
of    O
rhabdoid    B-Malignancy114237561
tumors    I-Malignancy114237561
,    O
commonly    O
affecting    O
pediatric    O
population    O
.    O

Rhabdoid    B-Malignancy114237561
tumor    I-Malignancy114237561
,    O
which    O
accounts    O
for    O
5    O
-    O
510%    O
of    O
childhood    O
kidney    O
neoplasms    O
,    O
occurs    O
predominantly    O
in    O
children    O
from    O
1    O
to    O
2    O
years    O
of    O
age    O
.    O

Sebaceous    O
carcinomas    O
are    O
a    O
subset    O
of    O
a    O
larger    O
pathology    O
,    O
Muir-Torre    B-Malignancy114237561
syndrome    I-Malignancy114237561
.    O

Muir-Torre    B-Malignancy114237561
syndrome    I-Malignancy114237561
,    O
the    O
inherited    O
cancer    O
syndrome    O

Gliosarcoma    B-Malignancy114237561
is    O
a    O
rare    O
type    O
of    O
glioma    O
,    O
a    O
cancer    O
of    O
the    O
brain    O
that    O
comes    O
from    O
glial    O
,    O
or    O
supportive    O
,    O
brain    O
cells    O
,    O
as    O
opposed    O
to    O
the    O
neural    O
brain    O
cells    O
.    O

In    O
2008    O
,    O
a    O
gene    B-Malignancy114237561
mutation    I-Malignancy114237561
that    O
is    O
typically    O
found    O
only    O
in    O
Ashkenazi    O
Jews    O
,    O
and    O
is    O
linked    O
to    O
a    O
virulent    O
form    O
of    O
breast    O
cancer    O
in    O
women    O
,    O
was    O
discovered    O
in    O
a    O
cluster    O
of    O
Hispanic    O
Catholic    O
women    O
in    O
southern    O
Colorado    O
,    O
many    O
of    O
whom    O
trace    O
their    O
family    O
's    O
roots    O
to    O
northern    O
New    O
Mexico    O
.    O

BRCA    B-Malignancy114237561
mutation    I-Malignancy114237561
:    O
Harmful    O
mutations    O
in    O
the    O
"    O
BRCA1    O
"    O
and    O
"    O
BRCA2    O
"    O
genes    O
can    O
produce    O
very    O
high    O
rates    O
of    O
breast    O
and    O
ovarian    O
cancer    O
,    O
as    O
well    O
as    O
increased    O
rates    O
of    O
other    O
cancers    O
.    O

Myriad    O
Genetics    O
was    O
founded    O
in    O
1994    O
as    O
a    O
startup    O
company    O
out    O
of    O
University    O
of    O
Utah    O
,    O
by    O
scientists    O
involved    O
in    O
the    O
hunt    O
for    O
the    O
BRCA    B-Malignancy114237561
genes    O
.    O

Due    O
to    O
a    O
higher    O
prevalence    O
of    O
a    O
BRCA    B-Malignancy114237561
mutation    I-Malignancy114237561
,    O
Ashkenazi    O
Jews    O
have    O
a    O
higher    O
risk    O
of    O
developing    O
breast    O
cancer    O
.    O

The    O
Grays    O
donated    O
$    O
25    O
million    O
to    O
create    O
the    O
Basser    O
Research    O
Center    O
,    O
which    O
focuses    O
on    O
cancer    O
prevention    O
,    O
treatment    O
,    O
and    O
research    O
of    O
BRCA-related    B-Malignancy114237561
,    O
genetically    O
-    O
inherited    O
cancers    O
.    O

Howel–Evans    B-Malignancy114237561
syndrome    I-Malignancy114237561

A    O
unilateral    O
single    O
palmar    O
crease    O
was    O
also    O
reported    O
in    O
a    O
case    O
of    O
chromosome    O
9    O
mutation    O
causing    O
Nevoid    B-Malignancy114237561
basal    I-Malignancy114237561
cell    I-Malignancy114237561
carcinoma    I-Malignancy114237561
syndrome    I-Malignancy114237561
and    O
Robinow    O
syndrome    O
.    O

Blunted    O
metacarpals    O
(    O
particularly    O
the    O
fourth    O
metacarpal    O
)    O
are    O
a    O
symptom    O
of    O
Nevoid    B-Malignancy114237561
basal    I-Malignancy114237561
cell    I-Malignancy114237561
carcinoma    I-Malignancy114237561
syndrome    I-Malignancy114237561
.    O

Goltz–Gorlin    B-Malignancy114237561
syndrome    I-Malignancy114237561

Nevoid    B-Malignancy114237561
basal    I-Malignancy114237561
cell    I-Malignancy114237561
carcinoma    I-Malignancy114237561
syndrome    I-Malignancy114237561

Hereditary    O
causes    O
of    O
sebaceous    O
cysts    O
include    O
Gardner's    B-Malignancy114237561
syndrome    I-Malignancy114237561
and    O
basal    B-Malignancy114237561
cell    I-Malignancy114237561
nevus    I-Malignancy114237561
syndrome    I-Malignancy114237561
.    O

Basal    B-Malignancy114237561
cell    I-Malignancy114237561
nevus    I-Malignancy114237561
syndrome    I-Malignancy114237561

Gorlin    B-Malignancy114237561
syndrome    I-Malignancy114237561

BMPR1A    O
,    O
SMAD4    O
and    O
PTEN    O
are    O
responsible    O
for    O
juvenile    B-Malignancy114237561
polyposis    I-Malignancy114237561
syndrome    I-Malignancy114237561
,    O
juvenile    O
intestinal    O
polyposis    O
and    O
Cowden's    B-Malignancy114237561
disease    I-Malignancy114237561
.    O

Juvenile    B-Malignancy114237561
polyposis    I-Malignancy114237561
syndrome    I-Malignancy114237561
is    O
characterised    O
by    O
the    O
presence    O
of    O
more    O
than    O
five    O
polyps    O
in    O
the    O
colon    O
or    O
rectum    O
,    O
or    O
numerous    O
juvenile    O
polyps    O
throughout    O
the    O
gastrointestinal    O
tract    O
,    O
or    O
any    O
number    O
of    O
juvenile    O
polyps    O
in    O
any    O
person    O
with    O
a    O
family    O
history    O
of    O
juvenile    O
polyposis    O
.    O

It    O
has    O
been    O
chosen    O
by    O
Linus    O
Torvalds    O
as    O
the    O
logo    O
for    O
version    O
2.6.29    O
of    O
the    O
Linux    O
kernel    O
to    O
support    O
the    O
effort    O
to    O
save    O
the    O
Tasmanian    O
devil    O
species    O
from    O
extinction    O
due    O
to    O
the    O
devil    B-Malignancy114237561
facial    I-Malignancy114237561
tumour    I-Malignancy114237561
disease    I-Malignancy114237561
.    O

The    O
Tasmanian    O
devil    O
was    O
once    O
common    O
at    O
the    O
park    O
,    O
but    O
has    O
seen    O
a    O
significant    O
drop    O
in    O
density    O
due    O
to    O
the    O
devil    B-Malignancy114237561
facial    I-Malignancy114237561
tumour    I-Malignancy114237561
disease    I-Malignancy114237561
.    O

It    O
is    O
one    O
of    O
only    O
four    O
known    O
transmissible    B-Malignancy114237561
cancer    I-Malignancy114237561
;    O
another    O
is    O
devil    B-Malignancy114237561
facial    I-Malignancy114237561
tumor    I-Malignancy114237561
disease    I-Malignancy114237561
,    O
a    O
cancer    O
which    O
occurs    O
in    O
Tasmanian    O
devils    O
.    O

Sinonasal    B-Malignancy114237561
undifferentiated    I-Malignancy114237561
carcinoma    I-Malignancy114237561
,    O
abbreviated    O
SNUC    B-Malignancy114237561
,    O
is    O
a    O
rare    O
aggressive    O
type    O
of    O
cancer    O
that    O
arises    O
from    O
epithelium    O
or    O
lining    O
of    O
the    O
nose    O
or    O
sinuses    O
.    O

Harmful    O
mutations    O
in    O
these    O
genes    O
may    O
produce    O
a    O
hereditary    B-Malignancy114237561
breast-ovarian    I-Malignancy114237561
cancer    I-Malignancy114237561
syndrome    I-Malignancy114237561
in    O
affected    O
persons    O
.    O

Approximately    O
half    O
of    O
men    O
who    O
develop    O
breast    O
cancer    O
have    O
a    O
mutation    O
in    O
a    O
"    O
BRCA    O
"    O
gene    O
or    O
in    O
one    O
of    O
the    O
other    O
genes    O
associated    O
with    O
hereditary    B-Malignancy114237561
breast–ovarian    I-Malignancy114237561
cancer    I-Malignancy114237561
syndrome    I-Malignancy114237561
.    O

Also    O
called    O
ependymoma    B-Malignancy114237561
.    O

Neoplasia    O
also    O
includes    O
direct    O
seeding    O
of    O
the    O
cerebrospinal    O
fluid    O
(    O
CSF    O
)    O
from    O
primary    O
central    O
nervous    O
system    O
(    O
CNS    O
)    O
tumors    O
such    O
as    O
glioblastoma    O
multiforme    O
,    O
medulloblastoma    O
,    O
ependymoma    B-Malignancy114237561
,    O
and    O
choroid    O
plexus    O
carcinoma    O
.    O

In    O
September    O
2008    O
,    O
Bolston    O
was    O
diagnosed    O
with    O
spinal    O
ependymoma    B-Malignancy114237561
.    O

In    O
Europe    O
,    O
it    O
is    O
also    O
approved    O
for    O
the    O
treatment    O
of    O
Hodgkin    O
's    O
lymphoma    O
,    O
generalized    O
malignant    O
lymphoma    O
,    O
reticulocyte    O
sarcoma    O
,    O
acute    O
leukaemia    O
,    O
primary    O
brain    O
tumours    O
(    O
glioblastoma    O
,    O
ependymoma    B-Malignancy114237561
,    O
astrocytoma    O
)    O
,    O
bladder    O
cancer    O
,    O
neuroblastoma    O
and    O
other    O
solid    O
tumours    O
in    O
children    O
.    O

may    O
also    O
cause    O
non    O
-    O
endocrine    O
tumors    O
such    O
as    O
facial    O
angiofibromas    O
,    O
collagenomas    O
,    O
lipomas    O
,    O
meningiomas    O
,    O
ependymoma    B-Malignancy114237561
,    O
and    O
leiomyomas    O
.    O

Two    O
years    O
later    O
,    O
he    O
was    O
diagnosed    O
with    O
an    O
ependymoma    B-Malignancy114237561
,    O
a    O
tumor    O
that    O
arises    O
from    O
the    O
ependyma    O
.    O

HN-3    O
has    O
found    O
some    O
applications    O
in    O
chemotherapy    O
,    O
e.g.    O
,    O
for    O
Hodgkin's    B-Malignancy114237561
disease    I-Malignancy114237561
,    O
and    O
in    O
some    O
compound    O
Semiconductor    O
research    O
but    O
it    O
is    O
mainly    O
of    O
interest    O
for    O
its    O
military    O
uses    O
and    O
is    O
the    O
only    O
one    O
of    O
these    O
agents    O
that    O
remains    O
anywhere    O
as    O
a    O
military    O
agent    O
.    O

Similarly    O
,    O
an    O
enlarged    O
right    O
supraclavicular    O
lymph    O
node    O
tends    O
to    O
drain    O
thoracic    O
malignancies    O
such    O
as    O
lung    O
and    O
esophageal    O
cancer    O
,    O
as    O
well    O
as    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
.    O

the    O
discovery    O
of    O
vinblastine    O
as    O
successful    O
chemotherapy    O
for    O
Hodgkin    B-Malignancy114237561
lymphoma    I-Malignancy114237561
in    O
the    O
1950s    O
,    O
also    O
a    O
treatment    O
for    O
cancer    O
still    O
used    O
today    O

He    O
became    O
world    O
famous    O
for    O
his    O
contribution    O
to    O
the    O
curability    O
of    O
Hodgkin's    B-Malignancy114237561
disease    I-Malignancy114237561
and    O
to    O
cancer    O
education    O
.    O

Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
,    O
a    O
highly    O
treatable    O
hematological    O
malignancy    O
(    O
"    O
blood    O
cancer    O
"    O
)    O

On    O
April    O
30    O
,    O
2009    O
,    O
Zohn    O
was    O
diagnosed    O
with    O
a    O
rare    O
type    O
of    O
cancer    O
called    O
CD20-positive    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
.    O

Homer    O
returns    O
to    O
Coalwood    O
as    O
a    O
hero    O
and    O
visits    O
Miss    O
Riley    O
,    O
who    O
is    O
dying    O
of    O
Hodgkin's    B-Malignancy114237561
disease    I-Malignancy114237561
.    O

In    O
March    O
2008    O
he    O
was    O
diagnosed    O
with    O
Hodgkin's    B-Malignancy114237561
Disease    I-Malignancy114237561
.    O

His    O
name    O
was    O
attached    O
to    O
the    O
eponymous    O
Ebstein    O
's    O
anomaly    O
(    O
a    O
rare    O
congenital    O
heart    O
defect    O
)    O
and    O
Pel-Ebstein    B-Malignancy114237561
fever    I-Malignancy114237561
(    O
a    O
remittent    O
fever    O
associated    O
with    O
Hodgkin's    B-Malignancy114237561
disease    I-Malignancy114237561
)    O
.    O

They    O
were    O
a    O
very    O
successful    O
duo    O
until    O
2000    O
,    O
releasing    O
One    O
Hell    O
of    O
a    O
Video    O
,    O
D'Unbelievables    O
,    O
D'Video    O
,    O
D'Telly    O
,    O
D'Mother    O
and    O
D'collection    O
but    O
the    O
group    O
stopped    O
touring    O
after    O
Kenny    O
was    O
diagnosed    O
with    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
.    O

They    O
toured    O
extensively    O
all    O
over    O
Ireland    O
for    O
almost    O
a    O
decade    O
until    O
Jon    O
Kenny    O
was    O
diagnosed    O
with    O
Hodgkin's    B-Malignancy114237561
Disease    I-Malignancy114237561
in    O
2000    O
.    O

Paul    O
Allen    O
resigned    O
from    O
Microsoft    O
in    O
1983    O
after    O
developing    O
Hodgkin's    B-Malignancy114237561
disease    I-Malignancy114237561
.    O

In    O
Hodgkin    B-Malignancy114237561
lymphoma    I-Malignancy114237561
,    O
for    O
instance    O
,    O
the    O
typically    O
-    O
observed    O
eosinophilia    O
is    O
thought    O
to    O
be    O
attributable    O
to    O
an    O
increased    O
production    O
of    O
IL-5    O
.    O

Note    O
:    O
The    O
character    O
of    O
Daisy    O
,    O
played    O
by    O
Susan    O
Wokoma    O
,    O
was    O
introduced    O
when    O
Dominique    O
Moore    O
had    O
to    O
leave    O
the    O
show    O
during    O
recording    O
of    O
series    O
3    O
to    O
have    O
treatment    O
for    O
Hodgkin's    B-Malignancy114237561
Lymphoma    I-Malignancy114237561
.    O

Shortly    O
after    O
his    O
sophomore    O
year    O
in    O
1982    O
,    O
he    O
was    O
diagnosed    O
with    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
,    O
one    O
of    O
the    O
more    O
curable    O
types    O
of    O
cancer    O
when    O
discovered    O
in    O
its    O
early    O
stages    O
.    O

In    O
1965    O
,    O
he    O
discovered    O
he    O
had    O
Hodgkin’s    B-Malignancy114237561
lymphoma    I-Malignancy114237561
.    O

Huggins    O
has    O
argued    O
that    O
amalgam    O
can    O
cause    O
digestive    O
problems    O
such    O
as    O
Crohn    O
's    O
disease    O
and    O
ulcers    O
,    O
mood    O
disorders    O
such    O
as    O
depression    O
and    O
fatigue    O
,    O
autoimmune    O
diseases    O
such    O
as    O
multiple    O
sclerosis    O
,    O
scleroderma    O
and    O
lupus    O
,    O
high    O
or    O
low    O
blood    O
pressure    O
,    O
arthritis    O
,    O
tachycardia    O
,    O
mononucleosis    O
,    O
and    O
cancers    O
such    O
as    O
leukemia    O
and    O
Hodgkin's    B-Malignancy114237561
disease    I-Malignancy114237561
.    O

His    O
mother    O
died    O
of    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
when    O
he    O
was    O
eight    O
years    O
old    O
and    O
his    O
father    O
remarried    O
.    O

March    O
10    O
–    O
Louis    O
Sissman    O
,    O
48    O
,    O
of    O
Hodgkin's    B-Malignancy114237561
disease    I-Malignancy114237561

Mario    O
Lemieux    O
overcame    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
to    O
finish    O
his    O
NHL    O
career    O
with    O
more    O
than    O
1,700    O
points    O
and    O
two    O
championships    O
,    O
and    O
now    O
owns    O
the    O
Pittsburgh    O
Penguins    O
.    O

On    O
8    O
July    O
2003    O
,    O
at    O
the    O
age    O
of    O
18    O
,    O
Goodrem    O
was    O
diagnosed    O
with    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
.    O

The    O
drug    O
was    O
created    O
by    O
Tanox    O
under    O
the    O
name    O
"    O
TNX-650    O
"    O
,    O
and    O
a    O
phase    O
I    O
clinical    O
trial    O
for    O
refractory    O
Hodgkin’s    B-Malignancy114237561
lymphoma    I-Malignancy114237561
had    O
been    O
performed    O
when    O
Genentech    O
acquired    O
Tanox    O
in    O
2007    O
.    O

The    O
presence    O
of    O
these    O
cells    O
is    O
diagnostic    O
of    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
.    O

Glutathione    O
conjugates    O
of    O
14,15-HxA3    O
and    O
14,15-HxB3    O
have    O
also    O
been    O
detected    O
the    O
human    O
Hodgkin    B-Malignancy114237561
disease    I-Malignancy114237561
Reed–    O

He    O
died    O
of    O
Hodgkin's    B-Malignancy114237561
disease    I-Malignancy114237561
in    O
Minneapolis    O
,    O
Minnesota    O
.    O

The    O
Deveraux    O
Family    O
hired    O
Kayla    O
to    O
be    O
Jack    O
's    O
private    O
nurse    O
when    O
he    O
was    O
diagnosed    O
with    O
Hodgkin's    B-Malignancy114237561
Disease    I-Malignancy114237561
and    O
quite    O
ill    O
.    O

According    O
to    O
his    O
official    O
Facebook    O
page    O
,    O
Miller    O
was    O
very    O
sick    O
while    O
working    O
on    O
"    O
Mortuary    O
Massacre    O
"    O
,    O
and    O
in    O
July    O
of    O
2016    O
while    O
finalizing    O
the    O
edits    O
,    O
he    O
was    O
diagnosed    O
with    O
stage    O
3    O
Hodgkin's    B-Malignancy114237561
Lymphoma    I-Malignancy114237561
.    O

In    O
May    O
2016    O
,    O
the    O
FDA    O
approved    O
nivolumab    O
for    O
the    O
treatment    O
of    O
patients    O
with    O
classical    B-Malignancy114237561
Hodgkin    I-Malignancy114237561
lymphoma    I-Malignancy114237561
(    O
cHL    O
)    O
who    O
have    O
relapsed    O
or    O
progressed    O
after    O
autologous    O
hematopoietic    O
stem    O
cell    O
transplantation    O
(    O
auto    O
-    O
HSCT    O
)    O
and    O
post    O
-    O
transplantation    O
brentuximab    O
vedotin    O
.    O

In    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
,    O
Reed    O
-    O
Sternberg    O
cells    O
harbor    O
amplification    O
of    O
chromosome    O
9p24.1    O
,    O
which    O
encodes    O
PD    O
-    O
L1    O
and    O
PD    O
-    O
L2    O
and    O
leads    O
to    O
their    O
constitutive    O
expression    O
.    O

Hutchins    O
was    O
diagnosed    O
with    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
in    O
late    O
2012    O
,    O
which    O
was    O
treated    O
and    O
went    O
into    O
remission    O
by    O
July    O
2013    O
.    O

In    O
early    O
2013    O
Hutchins    O
announced    O
that    O
he    O
had    O
been    O
diagnosed    O
with    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
.    O

Ross    O
Hutchins    O
was    O
diagnosed    O
with    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
in    O
December    O
2012    O
,    O
and    O
took    O
an    O
indefinite    O
break    O
from    O
tennis    O
while    O
he    O
recovered    O
.    O

She    O
is    O
well    O
known    O
as    O
a    O
survivor    O
of    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
.    O

While    O
in    O
college    O
,    O
Padilla    O
was    O
diagnosed    O
with    O
Hodgkins    B-Malignancy114237561
Lymphoma    I-Malignancy114237561
and    O
underwent    O
several    O
rounds    O
of    O
chemotherapy    O
and    O
radiation    O
.    O

In    O
2011    O
Scheuer    O
,    O
who    O
was    O
at    O
the    O
time    O
twenty    O
-    O
eight    O
years    O
old    O
,    O
was    O
diagnosed    O
with    O
-    O
and    O
successfully    O
treated    O
for    O
-    O
stage    O
IV    O
Hodgkins    B-Malignancy114237561
Lymphoma    I-Malignancy114237561
.    O

Hodgkin's    B-Malignancy114237561
disease    I-Malignancy114237561

Chronic    O
lymphocytic    O
leukemia    O
may    O
transform    O
into    O
Richter    O
's    O
syndrome    O
,    O
the    O
development    O
of    O
fast    O
-    O
growing    O
diffuse    O
large    O
B    O
cell    O
lymphoma    O
,    O
prolymphocytic    O
leukemia    O
,    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
,    O
or    O
acute    O
leukemia    O
in    O
some    O
patients    O
.    O

December    O
2    O
–    O
Dinu    O
Lipatti    O
,    O
Romanian    O
pianist    O
and    O
composer    O
(    O
born    O
1917    O
;    O
Hodgkin's    B-Malignancy114237561
disease    I-Malignancy114237561
)    O

Delta    O
Goodrem    O
is    O
diagnosed    O
with    O
Hodgkin's    B-Malignancy114237561
Disease    I-Malignancy114237561
.    O

Dakhlalla    O
's    O
mother    O
died    O
due    O
to    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
in    O
2016    O
.    O

Kasdan    O
was    O
diagnosed    O
with    O
Hodgkin's    B-Malignancy114237561
disease    I-Malignancy114237561
when    O
he    O
was    O
a    O
17-year    O
-    O
old    O
junior    O
in    O
high    O
school    O
.    O

Tomography    O
,    O
often    O
assisted    O
by    O
a    O
computer    O
to    O
form    O
a    O
PET    O
/    O
CT    O
(    O
CT    O
stands    O
for    O
"    O
computer    O
tomography    O
"    O
)    O
machine    O
,    O
can    O
then    O
be    O
used    O
to    O
diagnose    O
or    O
monitor    O
treatment    O
of    O
cancers    O
,    O
especially    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
,    O
lung    O
cancer    O
,    O
and    O
breast    O
cancer    O
.    O

There    O
are    O
a    O
variety    O
of    O
conditions    O
that    O
cause    O
itching    O
and    O
skin    O
picking    O
including    O
:    O
eczema    O
,    O
psoriasis    O
,    O
diabetes    O
,    O
liver    O
disease    O
,    O
Hodgkin's    B-Malignancy114237561
disease    I-Malignancy114237561
,    O
polycythemia    O
vera    O
,    O
systemic    O
lupus    O
,    O
and    O
Prader    O
-    O
Willi    O
syndrome    O
.    O

He    O
was    O
also    O
involved    O
in    O
such    O
organizations    O
as    O
the    O
Houston    O
Area    O
Federal    O
Business    O
Association    O
,    O
the    O
Hodgkin's    B-Malignancy114237561
Disease    I-Malignancy114237561
Memorial    O
Research    O
Center    O
and    O
the    O
Texas    O
and    O
Harris    O
County    O
Young    O
Democrats    O
.    O

During    O
his    O
second    O
stint    O
with    O
the    O
Timberwolves    O
,    O
Saunders    O
was    O
diagnosed    O
with    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
.    O

On    O
August    O
11    O
,    O
2015    O
,    O
Saunders    O
announced    O
he    O
had    O
been    O
diagnosed    O
with    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
,    O
for    O
which    O
he    O
was    O
undergoing    O
treatment    O
;    O
Saunders    O
planned    O
to    O
remain    O
the    O
Timberwolves    O
'    O
head    O
coach    O
and    O
president    O
.    O

Interleukin-21    O
is    O
also    O
produced    O
by    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
(    O
HL    O
)    O
cancer    O
cells    O
(    O
which    O
is    O
surprising    O
because    O
IL-21    O
was    O
thought    O
to    O
be    O
produced    O
only    O
in    O
T    O
cells    O
)    O
.    O

McDowell    O
was    O
diagnosed    O
with    O
Hodgkin’s    B-Malignancy114237561
lymphoma    I-Malignancy114237561
in    O
March    O
and    O
Verzbicas    O
was    O
sure    O
that    O
he    O
would    O
have    O
won    O
the    O
world    O
title    O
in    O
2011    O
.    O

In    O
October    O
2003    O
,    O
Hall    O
was    O
diagnosed    O
with    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
;    O
he    O
died    O
on    O
14    O
February    O
2006    O
,    O
at    O
the    O
age    O
of    O
31    O
,    O
from    O
complications    O
resulting    O
from    O
the    O
stem    O
cell    O
transplant    O
he    O
received    O
in    O
January    O
2005    O
.    O

Thomas    O
Hodgkin    O
–    O
discoverer    O
of    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561

It    O
is    O
important    O
in    O
the    O
treatment    O
of    O
acute    O
lymphoblastic    O
leukemia    O
,    O
non    O
-    O
Hodgkin    O
lymphomas    O
,    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
,    O
multiple    O
myeloma    O
,    O
and    O
other    O
hormone    O
-    O
sensitive    O
tumors    O
,    O
in    O
combination    O
with    O
other    O
anticancer    O
drugs    O
.    O

Steinberg    O
's    O
father    O
died    O
of    O
Hodgkin's    B-Malignancy114237561
disease    I-Malignancy114237561
when    O
he    O
was    O
a    O
child    O
.    O

It    O
is    O
also    O
associated    O
with    O
particular    O
forms    O
of    O
cancer    O
,    O
such    O
as    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
,    O
Burkitt    O
's    O
lymphoma    O
,    O
gastric    O
cancer    O
,    O
nasopharyngeal    O
carcinoma    O
,    O
and    O
conditions    O
associated    O
with    O
human    O
immunodeficiency    O
virus    O
(    O
HIV    O
)    O
,    O
such    O
as    O
hairy    O
leukoplakia    O
and    O
central    O
nervous    O
system    O
lymphomas    O
.    O

Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
,    O
stomach    O
cancer    O
,    O
nasopharyngeal    O
carcinoma    O
,    O
multiple    O
sclerosis    O
,    O
and    O
lymphomatoid    O
granulomatosis    O
.    O

So    O
far    O
,    O
SMAC    O
overexpression    O
has    O
been    O
observed    O
to    O
oppose    O
cancer    O
progression    O
in    O
head    O
and    O
neck    O
squamous    O
cell    O
carcinoma    O
,    O
hepatocellular    O
carcinoma    O
,    O
Hodgkin    B-Malignancy114237561
lymphoma    I-Malignancy114237561
,    O
breast    O
cancer    O
,    O
glioblastoma    O
,    O
thyroid    O
cancer    O
,    O
renal    O
cell    O
carcinoma    O
,    O
testicular    O
germ    O
cell    O
tumors    O
,    O
colorectal    O
cancer    O
,    O
lung    O
cancer    O
,    O
bladder    O
cancer    O
,    O
endometrioid    O
endometrial    O
cancer    O
,    O
and    O
other    O
sarcomas    O
.    O

On    O
January    O
18    O
,    O
2008    O
,    O
Buechlein    O
was    O
diagnosed    O
with    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
,    O
more    O
commonly    O
known    O
as    O
Hodgkin    O
's    O
disease    O
,    O
having    O
experienced    O
heavy    O
fatigue    O
and    O
a    O
swelling    O
under    O
his    O
right    O
arm    O
and    O
then    O
undergoing    O
medical    O
tests    O
on    O
the    O
previous    O
January    O
13    O
.    O

Teniposide    O
(    O
trade    O
name    O
Vumon    O
)    O
is    O
a    O
chemotherapeutic    O
medication    O
used    O
in    O
the    O
treatment    O
of    O
childhood    O
acute    O
lymphocytic    O
leukemia    O
(    O
ALL    O
)    O
,    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
,    O
certain    O
brain    O
tumours    O
,    O
and    O
other    O
types    O
of    O
cancer    O
.    O

In    O
1963    O
,    O
Helmut    O
Schmidt    O
moved    O
the    O
family    O
to    O
Sydney    O
after    O
contracting    O
Hodgkin's    B-Malignancy114237561
disease    I-Malignancy114237561
and    O
they    O
found    O
a    O
home    O
in    O
the    O
suburb    O
of    O
West    O
Ryde    O
.    O

Zipnick    O
died    O
of    O
Hodgkin's    B-Malignancy114237561
disease    I-Malignancy114237561
in    O
1991    O
just    O
as    O
the    O
company    O
was    O
beginning    O
to    O
take    O
off    O
.    O

Other    O
causes    O
are    O
radiation    O
therapy    O
involving    O
the    O
spleen    O
,    O
such    O
as    O
that    O
used    O
to    O
treat    O
Hodgkin    B-Malignancy114237561
lymphoma    I-Malignancy114237561
.    O

Godfrey    O
has    O
a    O
tattoo    O
to    O
symbolize    O
her    O
successful    O
battle    O
with    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
,    O
which    O
the    O
producers    O
wrote    O
into    O
the    O
show    O
.    O

Stevens    O
died    O
in    O
2011    O
after    O
battling    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
.    O

Bogdanović    O
was    O
elected    O
to    O
office    O
in    O
2004    O
and    O
served    O
until    O
his    O
death    O
in    O
2007    O
of    O
Hodgkin's    B-Malignancy114237561
Disease    I-Malignancy114237561
.    O

In    O
January    O
2011    O
Anton    O
Buslov    O
was    O
diagnosed    O
with    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
.    O

During    O
2015    O
,    O
as    O
Campbell    O
fought    O
his    O
battle    O
with    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
and    O
embarked    O
on    O
a    O
100    O
date    O
tour    O
with    O
Def    O
Leppard    O
in    O
support    O
of    O
their    O
2015    O
self    O
-    O
titled    O
effort    O
,    O
Last    O
in    O
Line    O
did    O
not    O
tour    O
,    O
instead    O
they    O
finished    O
the    O
recording    O
of    O
their    O
debut    O
album    O
"    O
Heavy    O
Crown    O
"    O
.    O

Near    O
the    O
end    O
of    O
her    O
life    O
,    O
she    O
retreated    O
to    O
a    O
hermitage    O
in    O
Aegina    O
,    O
but    O
when    O
she    O
developed    O
Hodgkin's    B-Malignancy114237561
disease    I-Malignancy114237561
she    O
returned    O
to    O
Athens    O
.    O

The    O
Ki-67    O
protein    O
was    O
originally    O
defined    O
by    O
the    O
prototype    O
monoclonal    O
antibody    O
Ki-67    O
,    O
which    O
was    O
generated    O
by    O
immunizing    O
mice    O
with    O
nuclei    O
of    O
the    O
Hodgkin    B-Malignancy114237561
lymphoma    I-Malignancy114237561
cell    O
line    O
L428    O
.    O

Excluded    O
diseases    O
include    O
:    O
Hodgkin’s    B-Malignancy114237561
disease    I-Malignancy114237561
,    O
hairy    O
cell    O
leukaemia    O
,    O
chronic    O
lymphatic    O
leukaemia    O
(    O
CLL    O
)    O
,    O
malignant    O
melanoma    O
and    O
mesothelioma    O
.    O

He    O
was    O
a    O
collaborator    O
and    O
biographer    O
of    O
the    O
"    O
Three    O
Great    O
"    O
,    O
contemporary    O
physicians    O
who    O
worked    O
at    O
Guy    O
's    O
Hospital    O
,    O
Dr.    O
Thomas    O
Addison    O
,    O
the    O
discoverer    O
of    O
Addison    O
's    O
disease    O
,    O
Dr.    O
Richard    O
Bright    O
,    O
discoverer    O
of    O
Bright    O
's    O
disease    O
and    O
Dr.    O
Thomas    O
Hodgkin    O
,    O
discoverer    O
of    O
Hodgkin's    B-Malignancy114237561
lymphoma    I-Malignancy114237561
.    O

He    O
specializes    O
in    O
lymphoma    O
,    O
including    O
Non    O
-    O
Hodgkin    O
's    O
Lymphoma    O
,    O
Burkitt    O
's    O
Lymphoma    O
and    O
Hodgkin's    B-Malignancy114237561
Disease    I-Malignancy114237561
.    O

A    O
particular    O
disappointment    O
was    O
the    O
running    O
game    O
,    O
which    O
due    O
to    O
injuries    O
to    O
the    O
offensive    O
line    O
(    O
including    O
tackle    O
Karl    O
Nelson    O
missing    O
the    O
entire    O
season    O
due    O
to    O
Hodgkin's    B-Malignancy114237561
disease    I-Malignancy114237561
)    O
struggled    O
all    O
season    O
.    O

Secondary    O
lymphedema    O
is    O
a    O
condition    O
characterized    O
by    O
swelling    O
of    O
the    O
soft    O
tissues    O
in    O
which    O
an    O
excessive    O
amount    O
of    O
lymph    O
has    O
accumulated    O
,    O
and    O
is    O
caused    O
by    O
certain    O
malignant    O
diseases    O
such    O
as    O
Hodgkin's    B-Malignancy114237561
disease    I-Malignancy114237561
and    O
Kaposi    O
sarcoma    O
.    O

Yeo    O
taught    O
himself    O
to    O
paint    O
in    O
his    O
twenties    O
while    O
recovering    O
from    O
Hodgkin's    B-Malignancy114237561
Disease    I-Malignancy114237561
.    O

Later    O
diagnosed    O
with    O
Hodgkin's    B-Malignancy114237561
disease    I-Malignancy114237561
,    O
Pfost    O
was    O
admitted    O
to    O
Johns    O
Hopkins    O
Hospital    O
several    O
times    O
in    O
1965    O
,    O
and    O
died    O
there    O
on    O
August    O
11    O
at    O
age    O
59    O
.    O

Sarcoma    B-Malignancy114237561
botryoides    I-Malignancy114237561
or    O
botryoid    B-Malignancy114237561
sarcoma    I-Malignancy114237561
or    O
botryoid    B-Malignancy114237561
rhabdomyosarcoma    I-Malignancy114237561
is    O
a    O
subtype    O
of    O
embryonal    O
rhabdomyosarcoma    O
,    O
that    O
can    O
be    O
observed    O
in    O
the    O
walls    O
of    O
hollow    O
,    O
mucosa    O
lined    O
structures    O
such    O
as    O
the    O
nasopharynx    O
,    O
common    O
bile    O
duct    O
,    O
urinary    O
bladder    O
of    O
infants    O
and    O
young    O
children    O
or    O
the    O
vagina    O
in    O
females    O
,    O
typically    O
younger    O
than    O
age    O
8    O
.    O

Primary    B-Malignancy114237561
fallopian    I-Malignancy114237561
tube    I-Malignancy114237561
cancer    I-Malignancy114237561

Epithelial-myoepithelial    B-Malignancy114237561
carcinoma    I-Malignancy114237561
,    O
abbreviated    O
EMCa    B-Malignancy114237561
,    O
is    O
a    O
rare    O
malignant    O
tumour    O
that    O
typically    O
arises    O
in    O
a    O
salivary    O
gland    O
and    O
consists    O
of    O
both    O
an    O
epithelial    O
and    O
myoepithelial    O
component    O
.    O

She    O
has    O
two    O
sisters    O
,    O
Chris    O
and    O
Danielle    O
,    O
as    O
well    O
as    O
a    O
brother    O
,    O
Jeffery    O
,    O
who    O
died    O
of    O
childhood    B-Malignancy114237561
leukemia    I-Malignancy114237561
at    O
age    O
3    O
.    O

Since    O
becoming    O
a    O
model    O
,    O
Crawford    O
has    O
made    O
childhood    B-Malignancy114237561
leukemia    I-Malignancy114237561
a    O
focal    O
point    O
of    O
her    O
charity    O
work    O
,    O
donating    O
proceeds    O
of    O
her    O
calendars    O
to    O
medical    O
research    O
.    O

He    O
conducted    O
a    O
detailed    O
epidemiological    O
research    O
study    O
of    O
childhood    B-Malignancy114237561
leukemia    I-Malignancy114237561
cases    O
near    O
nuclear    O
facilities    O
and    O
the    O
hazards    O
of    O
working    O
with    O
tritium    O
.    O

Premature    O
aging    O
syndromes    O
including    O
Werner    O
syndrome    O
,    O
Ataxia    O
telangiectasia    O
,    O
Ataxia    O
-    O
telangiectasia    O
like    O
disorder    O
,    O
Bloom    B-Malignancy114237561
syndrome    I-Malignancy114237561
,    O
Fanconi    B-Malignancy114237561
anemia    I-Malignancy114237561
and    O
Nijmegen    O
breakage    O
syndrome    O
are    O
associated    O
with    O
short    O
telomeres    O
.    O

#    O
Today    O
's    O
Ashkenazi    O
Jews    O
suffer    O
from    O
a    O
number    O
of    O
congenital    O
diseases    O
and    O
mutations    O
at    O
higher    O
rates    O
than    O
most    O
other    O
ethnic    O
groups    O
;    O
these    O
include    O
Tay    O
-    O
Sachs    O
,    O
Gaucher    O
's    O
disease    O
,    O
Bloom's    B-Malignancy114237561
syndrome    I-Malignancy114237561
,    O
and    O
Fanconi    B-Malignancy114237561
anemia    I-Malignancy114237561
,    O
and    O
mutations    O
at    O
BRCA1    O
and    O
BRCA2    O
.    O

Bloom    B-Malignancy114237561
syndrome    I-Malignancy114237561
,    O
autosomal    O
recessive    O
human    O
genetic    O
disorder    O
that    O
predispose    O
patient    O
to    O
a    O
wide    O
variety    O
of    O
cancer    O

These    O
include    O
the    O
helicases    O
implicated    O
in    O
Bloom's    B-Malignancy114237561
and    O
Werner    O
's    O
syndromes    O
and    O
the    O
Saccharomyces    O
cerevisiae    O
protein    O
RAP1    O
.    O

Bloom    B-Malignancy114237561
syndrome    I-Malignancy114237561

Bloom    B-Malignancy114237561
syndrome    I-Malignancy114237561

They    O
are    O
also    O
seen    O
in    O
Gardner's    B-Malignancy114237561
syndrome    I-Malignancy114237561
and    O
Nevoid    O
Basal    O
Cell    O
Carcinoma    O
Syndrome    O
on    O
the    O
head    O
and    O
neck    O
.    O

The    O
combination    O
of    O
polyposis    O
,    O
osteomas    O
,    O
fibromas    O
and    O
sebaceous    O
cysts    O
is    O
termed    O
'    O
'    O
Gardner's    B-Malignancy114237561
syndrome    I-Malignancy114237561
"    O
(    O
with    O
or    O
without    O
abnormal    O
scarring    O
)    O
.    O

Gardner    B-Malignancy114237561
syndrome    I-Malignancy114237561
,    O
also    O
known    O
as    O
Gardner's    B-Malignancy114237561
syndrome    I-Malignancy114237561
or    O
familial    B-Malignancy114237561
colorectal    I-Malignancy114237561
polyposis    I-Malignancy114237561
,    O
is    O
an    O
autosomal    O
dominant    O
form    O
of    O
polyposis    O
characterized    O
by    O
the    O
presence    O
of    O
multiple    O
polyps    O
in    O
the    O
colon    O
together    O
with    O
tumors    O
outside    O
the    O
colon    O
.    O

Gardner's    B-Malignancy114237561
syndrome    I-Malignancy114237561
can    O
be    O
associated    O
with    O
failure    O
of    O
tooth    O
eruption    O
,    O
supernumerary    O
teeth    O
,    O
and    O
dentigerous    O
cysts    O
.    O

Wilms'    B-Malignancy114237561
tumor    I-Malignancy114237561
(    O
nephroblastoma    B-Malignancy114237561
)    O

Kidney    O
cancer    O
–    O
increased    O
risk    O
of    O
renal    O
cancer    O
,    O
especially    O
Wilms'    B-Malignancy114237561
tumor    I-Malignancy114237561
,    O
transitional    O
cell    O
carcinoma    O
,    O
and    O
an    O
occasional    O
case    O
report    O
of    O
carcinoid    O
tumor    O
.    O

A    O
variety    O
of    O
immunohistochemical    O
stains    O
are    O
used    O
by    O
pathologists    O
to    O
distinguish    O
neuroblastomas    O
from    O
histological    O
mimics    O
,    O
such    O
as    O
rhabdomyosarcoma    O
,    O
Ewing    O
's    O
sarcoma    O
,    O
lymphoma    O
and    O
Wilms'    B-Malignancy114237561
tumor    I-Malignancy114237561
.    O

It    O
has    O
been    O
associated    O
with    O
Wilms    B-Malignancy114237561
tumor    I-Malignancy114237561
.    O

Wilms'    B-Malignancy114237561
tumor    I-Malignancy114237561
,    O
a    O
cancer    O
of    O
the    O
kidneys    O
that    O
typically    O
occurs    O
in    O
children    O

Most    O
children    O
(    O
>    O
80%    O
)    O
with    O
BWS    O
do    O
not    O
develop    O
cancer    O
;    O
however    O
,    O
children    O
with    O
BWS    O
are    O
much    O
more    O
likely    O
(    O
~600    O
times    O
more    O
)    O
than    O
other    O
children    O
to    O
develop    O
certain    O
childhood    O
cancers    O
,    O
particularly    O
Wilms'    B-Malignancy114237561
tumor    I-Malignancy114237561
(    O
nephroblastoma    O
)    O
,    O
pancreatoblastoma    O
and    O
hepatoblastoma    B-Malignancy114237561
.    O

Denys    O
–    O
Drash    O
syndrome    O
(    O
DDS    O
)    O
or    O
Drash    O
syndrome    O
is    O
a    O
rare    O
disorder    O
or    O
syndrome    O
characterized    O
by    O
gonadal    O
dysgenesis    O
,    O
nephropathy    O
,    O
and    O
Wilms'    B-Malignancy114237561
tumor    I-Malignancy114237561
.    O

Wilms'    B-Malignancy114237561
tumor    I-Malignancy114237561

Pilhar    O
,    O
then    O
aged    O
six    O
,    O
suffered    O
from    O
Wilms'    B-Malignancy114237561
tumor    I-Malignancy114237561
.    O

The    O
best    O
-    O
studied    O
examples    O
in    O
this    O
context    O
are    O
carcinomas    O
of    O
the    O
prostate    O
,    O
brain    O
and    O
the    O
breast    O
and    O
nephroblastoma    B-Malignancy114237561
and    O
neuroendocrine    O
tumours    O
.    O

Wilm's    B-Malignancy114237561
tumor    I-Malignancy114237561
is    O
the    O
most    O
common    O
childhood    O
kidney    O
neoplasm    O
,    O
representing    O
some    O
85%    O
of    O
cases    O
.    O

At    O
16    O
months    O
old    O
,    O
Shamsavari    O
developed    O
Wilms'    B-Malignancy114237561
tumor    I-Malignancy114237561
,    O
a    O
tumor    O
of    O
the    O
kidneys    O
.    O

As    O
a    O
postdoc    O
,    O
he    O
started    O
to    O
study    O
Wilms'    B-Malignancy114237561
tumor    I-Malignancy114237561
and    O
characterized    O
the    O
tumor    O
suppressor    O
gene    O
WT1    O
and    O
WTX    O
.    O

"    O
A    O
rare    O
type    O
of    O
tumor    O
,    O
usually    O
of    O
the    O
female    O
genital    O
tract    O
,    O
in    O
which    O
the    O
insides    O
of    O
the    O
cells    O
look    O
clear    O
when    O
viewed    O
under    O
a    O
microscope    O
.    O
Also    O
called    O
clear    O
cell    O
adenocarcinoma    O
and    O
mesonephroma    B-Malignancy114237561
.    O
"    O

Clear-cell    B-Malignancy114237561
adenocarcinoma    I-Malignancy114237561
(    O
CCA    O
)    O
of    O
the    O
vagina    O
(    O
or    O
cervix    O
)    O
is    O
a    O
rare    O
Adenocarcinoma    O
(    O
cancer    O
)    O
often    O
linked    O
to    O
diethylstilbestrol    O
(    O
DES    O
)    O
,    O
a    O
drug    O
which    O
was    O
prescribed    O
in    O
the    O
mistaken    O
belief    O
that    O
it    O
prevented    O
miscarriage    O
and    O
ensured    O
a    O
healthy    O
pregnancy    O
.    O

Ureteral    B-Malignancy114237561
cancer    I-Malignancy114237561

#    O
Today    O
's    O
Ashkenazi    O
Jews    O
suffer    O
from    O
a    O
number    O
of    O
congenital    O
diseases    O
and    O
mutations    O
at    O
higher    O
rates    O
than    O
most    O
other    O
ethnic    O
groups    O
;    O
these    O
include    O
Tay    O
-    O
Sachs    O
,    O
Gaucher    O
's    O
disease    O
,    O
Bloom's    B-Malignancy114237561
syndrome    I-Malignancy114237561
,    O
and    O
Fanconi    B-Malignancy114237561
anemia    I-Malignancy114237561
,    O
and    O
mutations    O
at    O
BRCA1    O
and    O
BRCA2    O
.    O

Bone    O
marrow    O
failure    O
is    O
associated    O
with    O
three    O
types    O
of    O
diseases    O
,    O
Fanconi    B-Malignancy114237561
anemia    I-Malignancy114237561
(    O
FA    O
)    O
,    O
dyskeratosis    O
congenita    O
,    O
and    O
aplastic    O
anemia    O
.    O

In    O
case    O
of    O
an    O
inherited    O
condition    O
,    O
several    O
syndromes    O
are    O
known    O
for    O
an    O
association    O
with    O
radial    O
dysplasia    O
,    O
such    O
as    O
the    O
cardiovascular    O
Holt    O
-    O
Oram    O
syndrome    O
,    O
the    O
gastrointestinal    O
VATER    O
syndrome    O
and    O
the    O
hematologic    O
Fanconi    B-Malignancy114237561
anemia    I-Malignancy114237561
and    O
TAR    O
syndrome    O
.    O

Fanconi    B-Malignancy114237561
anaemia    I-Malignancy114237561
(    O
FA    B-Malignancy114237561
)    O
is    O
a    O
rare    O
genetic    O
disease    O
resulting    O
in    O
impaired    O
response    O
to    O
DNA    O
damage    O
.    O

Fanconi's    B-Malignancy114237561
anaemia    I-Malignancy114237561

Diamond    O
syndrome    O
,    O
in    O
which    O
the    O
bone    O
marrow    O
defect    O
results    O
primarily    O
in    O
neutropenia    O
,    O
and    O
Fanconi    B-Malignancy114237561
anemia    I-Malignancy114237561
,    O
where    O
all    O
cell    O
lines    O
are    O
affected    O
resulting    O
in    O
pancytopenia    O
.    O

Studies    O
in    O
"    O
Xenopus    O
"    O
egg    O
extracts    O
have    O
also    O
yielded    O
critical    O
insights    O
into    O
the    O
mechanism    O
of    O
action    O
of    O
human    O
disease    O
genes    O
associated    O
with    O
genetic    O
instability    O
and    O
elevated    O
cancer    O
risk    O
,    O
such    O
as    O
ataxia    O
telangiectasia    O
,    O
"    O
BRCA1    O
"    O
inherited    O
breast    O
and    O
ovarian    O
cancer    O
,    O
"    O
Nbs1    O
"    O
Nijmegen    O
breakage    O
syndrome    O
,    O
"    O
RecQL4    O
"    O
Rothmund    O
-    O
Thomson    O
syndrome    O
,    O
"    O
c    O
-    O
Myc    O
"    O
oncogene    O
and    O
FANC    O
proteins    O
(    O
Fanconi    B-Malignancy114237561
anemia    I-Malignancy114237561
)    O
.    O

BRCA2    O
"    O
mutations    O
produces    O
Fanconi    B-Malignancy114237561
anemia    I-Malignancy114237561
.    O

Tommy    O
suffers    O
from    O
Fanconi    B-Malignancy114237561
anemia    I-Malignancy114237561
,    O
a    O
rare    O
genetic    O
blood    O
disorder    O
with    O
no    O
cure    O
.    O

Mutations    O
in    O
the    O
gene    O
are    O
associated    O
with    O
the    O
disease    O
Fanconi    B-Malignancy114237561
anemia    I-Malignancy114237561
.    O

Fanconi    B-Malignancy114237561
anemia    I-Malignancy114237561

Fanconi    B-Malignancy114237561
anemia    I-Malignancy114237561

The    O
book    O
tells    O
the    O
story    O
of    O
her    O
family    O
's    O
pioneering    O
use    O
of    O
in    O
vitro    O
fertilization    O
and    O
Preimplantation    O
genetic    O
diagnosis    O
to    O
try    O
to    O
save    O
the    O
life    O
of    O
her    O
son    O
,    O
Henry    O
Strongin    O
Goldberg    O
,    O
who    O
was    O
born    O
with    O
the    O
genetic    O
disease    O
Fanconi    B-Malignancy114237561
anemia    I-Malignancy114237561
.    O

Love    O
Your    O
Melon    O
is    O
an    O
American    O
hat    O
and    O
apparel    O
company    O
that    O
donates    O
50%    O
of    O
its    O
profits    O
to    O
benefit    O
children    O
with    O
pediatric    B-Malignancy114237561
cancer    I-Malignancy114237561
in    O
the    O
US    O
.    O

As    O
of    O
2016    O
,    O
Fox    O
21    O
News    O
claims    O
the    O
company    O
has    O
donated    O
20,000    O
hats    O
,    O
and    O
raised    O
over    O
$    O
1.2    O
million    O
for    O
pediatric    B-Malignancy114237561
cancer    I-Malignancy114237561
research    O
.    O

Usage    O
of    O
assisted    O
reproductive    O
technology    O
including    O
ovarian    O
stimulation    O
and    O
in    O
vitro    O
fertilization    O
have    O
been    O
associated    O
with    O
an    O
increased    O
overall    O
risk    O
of    O
childhood    B-Malignancy114237561
cancer    I-Malignancy114237561
in    O
the    O
offspring    O
,    O
which    O
may    O
be    O
caused    O
by    O
the    O
same    O
original    O
disease    O
or    O
condition    O
that    O
caused    O
the    O
infertility    O
or    O
subfertility    O
in    O
the    O
mother    O
or    O
father    O
.    O

The    O
hospital    O
is    O
a    O
leader    O
in    O
several    O
specialties    O
including    O
neonatal    O
care    O
,    O
pediatric    B-Malignancy114237561
oncology    I-Malignancy114237561
,    O
pediatric    O
cardiology    O
,    O
pediatric    O
surgery    O
,    O
and    O
pediatric    O
trauma    O
.    O

Overall    O
,    O
IVF    O
does    O
not    O
cause    O
an    O
increased    O
risk    O
of    O
childhood    B-Malignancy114237561
cancer    I-Malignancy114237561
.    O

This    O
commitment    O
resulted    O
in    O
a    O
partnership    O
beginning    O
in    O
2011    O
with    O
St.    O
Baldrick    O
's    O
Foundation    O
,    O
a    O
nonprofit    O
organization    O
that    O
raises    O
money    O
for    O
childhood    B-Malignancy114237561
cancer    I-Malignancy114237561
research    O
by    O
hosting    O
worldwide    O
head    O
-    O
shaving    O
events    O
.    O

She    O
is    O
internationally    O
considered    O
one    O
of    O
the    O
founders    O
of    O
Pediatric    B-Malignancy114237561
oncology    I-Malignancy114237561

The    O
Child    O
Cancer    O
Foundation    O
is    O
a    O
New    O
Zealand    O
-    O
based    O
charity    O
that    O
offers    O
support    O
to    O
children    B-Malignancy114237561
with    I-Malignancy114237561
cancer    I-Malignancy114237561
and    O
their    O
families    O
.    O

#    O
Create    O
awareness    O
of    O
childhood    B-Malignancy114237561
cancer    I-Malignancy114237561
in    O
Singapore    O

Muraro    O
wrote    O
her    O
memoir    O
in    O
1999    O
;    O
she    O
died    O
in    O
2014    O
of    O
bone    B-Malignancy114237561
marrow    I-Malignancy114237561
cancer    I-Malignancy114237561
.    O

Leukemia    O
Research    O
is    O
a    O
monthly    O
peer    O
-    O
reviewed    O
medical    O
journal    O
covering    O
research    O
on    O
hematologic    B-Malignancy114237561
malignancies    I-Malignancy114237561
.    O

On    O
February    O
19    O
,    O
2010    O
,    O
his    O
office    O
announced    O
that    O
Lautenberg    O
had    O
been    O
diagnosed    O
with    O
a    O
diffuse    O
large    O
b    O
-    O
cell    O
lymphoma    O
(    O
an    O
aggressive    O
but    O
curable    O
blood    B-Malignancy114237561
cancer    I-Malignancy114237561
that    O
appears    O
in    O
organs    O
like    O
the    O
stomach    O
)    O
at    O
Mount    O
Sinai    O
Medical    O
Center    O
in    O
New    O
York    O
.    O

Dexamethasone    O
is    O
also    O
used    O
as    O
a    O
direct    O
chemotherapeutic    O
agent    O
in    O
certain    O
haematological    B-Malignancy114237561
malignancies    I-Malignancy114237561
,    O
especially    O
in    O
the    O
treatment    O
of    O
multiple    O
myeloma    O
,    O
in    O
which    O
dexamethasone    O
is    O
given    O
alone    O
or    O
in    O
combination    O
with    O
other    O
chemotherapeutic    O
drugs    O
,    O
including    O
most    O
commonly    O
with    O
thalidomide    O
(    O
Thal    O
-    O
dex    O
)    O
,    O
lenalidomide    O
,    O
bortezomib    O
(    O
Velcade    O
,    O
Vel    O
-    O
dex    O
)    O
,    O
or    O
a    O
combination    O
of    O
doxorubicin    O
(    O
Adriamycin    O
)    O
and    O
vincristine    O
or    O
bortezomib    O
/    O
lenalidomide    O
/    O
dexamethasone    O
.    O

Mutations    O
in    O
"    O
BRCA1    O
"    O
and    O
"    O
BRCA2    O
"    O
are    O
strongly    O
implicated    O
in    O
some    O
hematological    B-Malignancy114237561
malignancies    I-Malignancy114237561
.    O

The    O
HEADstrong    O
Foundation    O
is    O
a    O
charitable    O
non    O
-    O
profit    O
organization    O
dedication    O
to    O
research    O
in    O
finding    O
a    O
cure    O
for    O
blood    B-Malignancy114237561
cancer    I-Malignancy114237561
and    O
to    O
help    O
families    O
affected    O
by    O
the    O
disease    O
.    O

This    O
treatment    O
can    O
be    O
used    O
in    O
hematological    B-Malignancy114237561
malignancy    I-Malignancy114237561
;    O
leukemia    O
and    O
lymphomas    O
including    O
hairy    O
cell    O
leukemia    O
,    O
chronic    O
myeloid    O
leukemia    O
,    O
nodular    O
lymphoma    O
,    O
and    O
cutaneous    O
T    O
-    O
cell    O
lymphoma    O
.    O

She    O
was    O
part    O
of    O
the    O
International    O
Working    O
Group    O
on    O
Morphology    O
of    O
MDS    O
and    O
also    O
in    O
the    O
group    O
which    O
devised    O
the    O
2008    O
WHO    O
classification    O
of    O
tumours    B-Malignancy114237561
of    I-Malignancy114237561
the    I-Malignancy114237561
lymphoid    I-Malignancy114237561
haematopoietic    I-Malignancy114237561
systems    I-Malignancy114237561
.    O

In    O
1993    O
he    O
surprised    O
the    O
scientific    O
world    O
by    O
hypothesizing    O
that    O
angiogenesis    O
is    O
as    O
important    O
in    O
blood    B-Malignancy114237561
cancers    I-Malignancy114237561
as    O
it    O
is    O
in    O
solid    O
tumors    O
,    O
and    O
the    O
next    O
year    O
he    O
published    O
work    O
showing    O
that    O
a    O
biomarker    O
of    O
angiogenesis    O
was    O
higher    O
in    O
all    O
people    O
with    O
cancer    O
,    O
but    O
especially    O
high    O
in    O
people    O
with    O
blood    O
cancers    O
,    O
and    O
other    O
evidence    O
of    O
the    O
role    O
of    O
angiogenesis    O
in    O
blood    O
cancers    O
emerged    O
as    O
well    O
.    O

Of    O
the    O
various    O
tumors    B-Malignancy114237561
of    I-Malignancy114237561
the    I-Malignancy114237561
blood    I-Malignancy114237561
and    I-Malignancy114237561
lymph    I-Malignancy114237561
,    O
cancers    O
of    O
WBCs    O
can    O
be    O
broadly    O
classified    O
as    O
leukemias    O
and    O
lymphomas    O
,    O
although    O
those    O
categories    O
overlap    O
and    O
are    O
often    O
grouped    O
as    O
a    O
pair    O
.    O

Supinyo    O
's    O
father    O
died    O
since    O
he    O
was    O
4    O
years    O
old    O
due    O
to    O
Hematological    B-Malignancy114237561
malignancy    I-Malignancy114237561
.    O

The    O
disorder    O
may    O
be    O
caused    O
either    O
by    O
a    O
genetic    O
disorder    O
or    O
indirectly    O
as    O
part    O
of    O
myelodysplastic    O
syndrome    O
,    O
which    O
can    O
evolve    O
into    O
hematological    B-Malignancy114237561
malignancies    I-Malignancy114237561
(    O
especially    O
acute    O
myelogenous    O
leukemia    O
)    O
.    O

Since    O
the    O
'    O
90s    O
immunophenotyping    O
(    O
staining    O
cells    O
with    O
antibodies    O
conjugated    O
with    O
fluorochromes    O
and    O
detection    O
with    O
flow    O
cytometer    O
)    O
became    O
the    O
preferred    O
method    O
in    O
diagnostics    O
of    O
haematological    B-Malignancy114237561
malignancies    I-Malignancy114237561
.    O

Eight    O
-    O
color    O
panels    O
for    O
diagnoses    O
,    O
and    O
classification    O
and    O
follow    O
-    O
up    O
of    O
haematological    B-Malignancy114237561
malignancies    I-Malignancy114237561
were    O
established    O
.    O

An    O
underlying    O
condition    O
(    O
streptococcal    O
infection    O
,    O
inflammatory    O
bowel    O
disease    O
,    O
nonlymphocytic    O
leukemia    O
and    O
other    O
hematologic    B-Malignancy114237561
malignancies    I-Malignancy114237561
,    O
solid    O
tumors    O
,    O
pregnancy    O
)    O
is    O
found    O
in    O
up    O
to    O
50%    O
of    O
cases    O
.    O

In    O
1988    O
,    O
Goldman    O
became    O
a    O
member    O
of    O
the    O
blood    B-Malignancy114237561
cancer    I-Malignancy114237561
charity    O
and    O
bone    O
marrow    O
transplant    O
register    O
Anthony    O
Nolan    O
.    O

He    O
died    O
in    O
New    O
York    O
after    O
a    O
prolonged    O
battle    O
with    O
bone    B-Malignancy114237561
marrow    I-Malignancy114237561
cancer    I-Malignancy114237561
.    O

The    O
Walter    O
and    O
Eliza    O
Hall    O
Institute    O
of    O
Medical    O
Research    O
,    O
more    O
commonly    O
known    O
as    O
the    O
Walter    O
and    O
Eliza    O
Hall    O
Institute    O
,    O
abbreviated    O
as    O
WEHI    O
,    O
is    O
Australia    O
's    O
oldest    O
medical    O
research    O
institute    O
.    O
,    O
the    O
institute    O
hosted    O
more    O
than    O
750    O
researchers    O
who    O
work    O
to    O
understand    O
,    O
prevent    O
and    O
treat    O
diseases    O
including    O
blood    B-Malignancy114237561
,    O
breast    O
and    O
ovarian    O
cancers    O
;    O
inflammatory    O
diseases    O
(    O
autoimmunity    O
)    O
such    O
as    O
rheumatoid    O
arthritis    O
,    O
type    O
1    O
diabetes    O
and    O
coeliac    O
disease    O
;    O
and    O
infectious    O
diseases    O
such    O
as    O
malaria    O
,    O
HIV    O
and    O
hepatitis    O
B    O
and    O
C.    O

August    O
18    O
–    O
Sepp    O
Daxenberger    O
,    O
48    O
,    O
German    O
politician    O
,    O
bone    B-Malignancy114237561
marrow    I-Malignancy114237561
cancer    I-Malignancy114237561
.    O

Arrhenoblastoma    B-Malignancy114237561

Sertoli-Leydig    B-Malignancy114237561
cell    I-Malignancy114237561
tumour    I-Malignancy114237561

Sertoli-Leydig    B-Malignancy114237561
cell    I-Malignancy114237561
tumour    I-Malignancy114237561
is    O
part    O
of    O
the    O
sex    O
cord    O
-    O
stromal    O
tumour    O
group    O
of    O
ovarian    O
neoplasms    O
.    O

Ovarian    O
tumors    O
such    O
as    O
granulosa    B-Malignancy114237561
tumor    I-Malignancy114237561
,    O
thecomas    O
,    O
Sertoli–Leydig    B-Malignancy114237561
cell    I-Malignancy114237561
tumor    I-Malignancy114237561
(    O
androblastomas    O
)    O
,    O
and    O
gynandroblastomas    O
,    O
as    O
well    O
as    O
ovarian    O
cancer    O
.    O

The    O
most    O
common    O
types    O
are    O
Meibomian    O
gland    O
adenoma    O
(    O
eyelid    O
)    O
,    O
papilloma    O
(    O
eyelid    O
)    O
,    O
melanoma    O
(    O
eyelid    O
,    O
conjunctiva    O
,    O
sclera    O
,    O
iris    O
,    O
ciliary    O
body    O
,    O
choroid    O
)    O
,    O
squamous    O
cell    O
carcinoma    O
(    O
conjunctiva    O
)    O
,    O
adenoma    O
(    O
ciliary    O
body    O
)    O
,    O
adenocarcinoma    O
(    O
ciliary    O
body    O
)    O
,    O
lymphoma    O
(    O
retina    O
,    O
choroid    O
,    O
ciliary    O
body    O
)    O
,    O
medulloepithelioma    O
(    O
retina    O
,    O
choroid    O
)    O
,    O
ganglioglioma    B-Malignancy114237561
(    O
retina    O
,    O
choroid    O
)    O
,    O
osteosarcoma    O
(    O
orbit    O
)    O
,    O
mast    O
cell    O
tumor    O
(    O
orbit    O
)    O
,    O
and    O
optic    O
nerve    O
sheath    O
meningioma    O
.    O

Lhermitte    O
–    O
Duclos    O
disease    O
(    O
LDD    O
)    O
,    O
also    O
called    O
dysplastic    O
gangliocytoma    O
of    O
the    O
cerebellum    O
,    O
is    O
a    O
rare    O
,    O
slowly    O
growing    O
tumor    O
of    O
the    O
cerebellum    O
,    O
a    O
gangliocytoma    B-Malignancy114237561
sometimes    O
considered    O
to    O
be    O
a    O
hamartoma    O
,    O
characterized    O
by    O
diffuse    O
hypertrophy    O
of    O
the    O
granular    O
layer    O
of    O
the    O
cerebellum    O
.    O

The    O
small    O
minority    O
of    O
tumors    O
that    O
arise    O
elsewhere    O
in    O
the    O
pancreas    O
are    O
mainly    O
pancreatic    B-Malignancy114237561
neuroendocrine    I-Malignancy114237561
tumor    I-Malignancy114237561
(    O
PanNETs    O
)    O
.    O

The    O
genes    O
often    O
found    O
mutated    O
in    O
PanNETs    B-Malignancy114237561
are    O
different    O
from    O
those    O
in    O
exocrine    O
pancreatic    O
cancer    O
.    O

Progressive    O
or    O
metastatic    O
pancreatic    B-Malignancy114237561
neuroendocrine    I-Malignancy114237561
tumor    I-Malignancy114237561
not    O
surgically    O
removable    O
(    O
May    O
2011    O
)    O

Clonally    B-Malignancy114237561
transmissible    I-Malignancy114237561
cancer    I-Malignancy114237561

It    O
is    O
one    O
of    O
only    O
four    O
known    O
transmissible    B-Malignancy114237561
cancer    I-Malignancy114237561
;    O
another    O
is    O
devil    B-Malignancy114237561
facial    I-Malignancy114237561
tumor    I-Malignancy114237561
disease    I-Malignancy114237561
,    O
a    O
cancer    O
which    O
occurs    O
in    O
Tasmanian    O
devils    O
.    O

Hemangiosarcoma    B-Malignancy114237561

Angiopoietin-2    O
is    O
elevated    O
in    O
patients    O
with    O
angiosarcoma    B-Malignancy114237561
.    O

cardiac    B-Malignancy114237561
sarcoma    I-Malignancy114237561
,    O
in    O
1978    O
,    O
at    O
the    O
age    O
of    O
26    O
.    O

It    O
is    O
sometimes    O
considered    O
equivalent    O
to    O
plasma    B-Malignancy114237561
cell    I-Malignancy114237561
dyscrasia    I-Malignancy114237561
.    O

Plasma    B-Malignancy114237561
cell    I-Malignancy114237561
dyscrasia    I-Malignancy114237561

It    O
is    O
a    O
plasma    B-Malignancy114237561
cell    I-Malignancy114237561
dyscrasia    I-Malignancy114237561
,    O
resembling    O
leukemia    O
,    O
with    O
cells    O
of    O
lymphocytic    O
,    O
plasmacytic    O
,    O
or    O
intermediate    O
morphology    O
,    O
which    O
secrete    O
a    O
monoclonal    O
immunoglobulin    O
M    O
component    O
.    O

Multiple    B-Malignancy114237561
endocrine    I-Malignancy114237561
neoplasia    I-Malignancy114237561
type    I-Malignancy114237561
2a    I-Malignancy114237561

Multiple    B-Malignancy114237561
endocrine    I-Malignancy114237561
neoplasia    I-Malignancy114237561
type    I-Malignancy114237561
2    I-Malignancy114237561
(    O
MEN2    B-Malignancy114237561
)    O
(    O
also    O
known    O
as    O
"    O
Pheochromocytoma    O
and    O
amyloid    O
producing    O
medullary    O
thyroid    O
carcinoma    O
"    O
,    O
"    O
PTC    O
syndrome    O
,    O
"    O
and    O
"    O
Sipple    O
syndrome    O
"    O
)    O
is    O
a    O
group    O
of    O
medical    O
disorders    O
associated    O
with    O
tumors    O
of    O
the    O
endocrine    O
system    O
.    O

MEN2    O
includes    O
MEN2A    B-Malignancy114237561
,    O
MEN2B    B-Malignancy114237561
and    O
familial    O
medullary    O
thyroid    O
cancer    O
(    O
FMTC    O
)    O
.    O

While    O
these    O
neoplasias    O
are    O
often    O
benign    O
(    O
in    O
contrast    O
to    O
tumours    O
occurring    O
in    O
MEN2A    B-Malignancy114237561
)    O
,    O
they    O
are    O
adenomas    O
and    O
,    O
therefore    O
,    O
produce    O
endocrine    O
phenotypes    O
.    O

Peutz-Jeghers    B-Malignancy114237561
syndrome    I-Malignancy114237561
—    O
an    O
autosomal    O
dominant    O
disorder    O
characterized    O
by    O
hyperpigmented    O
macules    O
on    O
the    O
lips    O
and    O
oral    O
mucosa    O
and    O
gastrointestinal    O
polyps    O
.    O

Peutz-Jeghers    B-Malignancy114237561
syndrome    I-Malignancy114237561

"    O
Peutz-Jeghers    B-Malignancy114237561
syndrome    I-Malignancy114237561
"    O
is    O
associated    O
with    O
polyps    O
of    O
the    O
GI    O
tract    O
and    O
also    O
increased    O
pigmentation    O
around    O
the    O
lips    O
,    O
genitalia    O
,    O
buccal    O
mucosa    O
feet    O
and    O
hands    O
.    O

File    O
:    O
Peutz    O
-    O
Jeghers    O
syndrome    O
polyp.jpg|Micrograph    O
of    O
a    O
Peutz-Jeghers    B-Malignancy114237561
colonic    I-Malignancy114237561
polyp    I-Malignancy114237561
-    O
a    O
type    O
of    O
hamartomatous    O
polyp    O
.    O
H&E    O
stain    O
.    O

Peutz–Jeghers    B-Malignancy114237561
syndrome    I-Malignancy114237561
can    O
cause    O
dark    O
spots    O
on    O
the    O
oral    O
mucosa    O
or    O
on    O
the    O
lips    O
or    O
the    O
skin    O
around    O
the    O
mouth    O
.    O

Hyperviscosity    O
occurs    O
from    O
pathologic    O
changes    O
of    O
either    O
cellular    O
or    O
protein    O
fractions    O
of    O
the    O
blood    O
such    O
as    O
is    O
found    O
in    O
polycythemias    O
,    O
multiple    O
myeloma    O
(    O
particularly    O
IgA    O
and    O
IgG3    O
)    O
,    O
leukemia    O
,    O
monoclonal    O
gammopathies    O
such    O
as    O
Waldenström    B-Malignancy114237561
macroglobulinemia    I-Malignancy114237561
,    O
sickle    O
cell    O
anemia    O
,    O
and    O
sepsis    O
.    O

Waldenström    B-Malignancy114237561
macroglobulinemia    I-Malignancy114237561

Lymphoplasmacytic    B-Malignancy114237561
lymphoma    I-Malignancy114237561

Others    O
may    O
make    O
blood    O
too    O
viscous    O
to    O
flow    O
smoothly    O
(    O
usually    O
with    O
IgM    O
pentamer    O
macroglobulins    O
)    O
,    O
a    O
phenomenon    O
known    O
as    O
Waldenström    B-Malignancy114237561
macroglobulinemia    I-Malignancy114237561
.    O

Waldenström    B-Malignancy114237561
macroglobulinemia    I-Malignancy114237561

Elevated    O
levels    O
of    O
macroglobulins    O
(    O
macroglobulinemia    O
)    O
may    O
cause    O
manifestations    O
of    O
excess    O
blood    O
viscosity    O
(    O
as    O
is    O
the    O
case    O
for    O
IgM    O
antibodies    O
in    O
Waldenström    B-Malignancy114237561
macroglobulinemia    I-Malignancy114237561
)    O
and/or    O
precipitate    O
within    O
blood    O
vessels    O
when    O
temperature    O
drops    O
(    O
as    O
in    O
cryoglobulinaemia    O
)    O
.    O

Waldenström's    B-Malignancy114237561
macroglobulinemia    I-Malignancy114237561
,    O
a    O
rare    O
form    O
of    O
blood    O
cancer    O

He    O
was    O
directing    O
a    O
catalogue    O
raisonné    O
on    O
Albert    O
Gleizes    O
when    O
he    O
was    O
diagnosed    O
with    O
Waldenström's    B-Malignancy114237561
macroglobulinemia    I-Malignancy114237561
,    O
a    O
cancer    O
of    O
the    O
lymphatic    O
system    O
.    O

On    O
August    O
11    O
,    O
2007    O
,    O
Kirsch    O
announced    O
on    O
his    O
personal    O
Web    O
site    O
that    O
he    O
had    O
been    O
diagnosed    O
with    O
Waldenstrom's    B-Malignancy114237561
macroglobulinemia    I-Malignancy114237561
,    O
a    O
rare    O
blood    O
cancer    O
.    O

Interest    O
in    O
using    O
BET    O
inhibitors    O
in    O
cancer    O
began    O
with    O
the    O
observation    O
that    O
chromosomal    O
translocations    O
involving    O
BET    O
genes    O
BRD3    O
and    O
BRD4    O
drove    O
the    O
pathogenesis    O
the    O
rare    O
cancer    O
NUT    B-Malignancy114237561
midline    I-Malignancy114237561
carcinoma    I-Malignancy114237561
.    O

NUT    B-Malignancy114237561
midline    I-Malignancy114237561
carcinoma    I-Malignancy114237561

Thymoma    O
and    O
thymic    B-Malignancy114237561
carcinoma    I-Malignancy114237561

These    O
tumours    O
are    O
rare    O
and    O
50%    O
to    O
70%    O
are    O
germinoma    B-Malignancy114237561
that    O
arise    O
from    O
sequestered    O
embryonic    O
germ    O
cells    O
.    O

Germinoma    B-Malignancy114237561

von    B-Malignancy114237561
Hippel-Lindau    I-Malignancy114237561
disease    I-Malignancy114237561
(    O
EUROCAT    O
Q85.82    O
)    O

He    O
also    O
conducted    O
research    O
of    O
eye    O
diseases    O
;    O
in    O
1874    O
he    O
made    O
an    O
early    O
observation    O
of    O
what    O
would    O
be    O
later    O
known    O
as    O
Von    B-Malignancy114237561
Hippel-Lindau    I-Malignancy114237561
syndrome    I-Malignancy114237561
,    O
and    O
in    O
1878    O
he    O
provided    O
an    O
early    O
clinical    O
description    O
of    O
proptosis    O
in    O
infantile    O
scurvy    O
.    O

It    O
is    O
usually    O
found    O
in    O
the    O
head    O
of    O
the    O
pancreas    O
,    O
and    O
may    O
be    O
associated    O
with    O
von    B-Malignancy114237561
Hippel-Lindau    I-Malignancy114237561
syndrome    I-Malignancy114237561
.    O

This    O
tumor    O
shows    O
a    O
very    O
high    O
association    O
with    O
von    B-Malignancy114237561
Hippel-Lindau    I-Malignancy114237561
syndrome    I-Malignancy114237561
(    O
VHL    O
)    O
.    O

Such    O
co    O
-    O
occurrences    O
are    O
usually    O
seen    O
in    O
patients    O
carrying    O
hereditary    O
syndromes    O
like    O
multiple    B-Malignancy114237561
endocrine    I-Malignancy114237561
neoplasia    I-Malignancy114237561
(    O
MEN    O
)    O
,    O
neurofibromatosis    O
1    O
(    O
NF1    O
)    O
,    O
or    O
von    B-Malignancy114237561
Hippel-Lindau    I-Malignancy114237561
(    O
VHL    O
)    O
disease    O
.    O

She    O
later    O
meets    O
Henry    O
Burton    O
,    O
a    O
patient    O
with    O
the    O
rare    O
genetic    O
condition    O
Von    B-Malignancy114237561
Hippel-Lindau    I-Malignancy114237561
disease    I-Malignancy114237561
,    O
who    O
can    O
no    O
longer    O
afford    O
to    O
pay    O
for    O
his    O
medical    O
care    O
.    O

Eugen    O
von    O
Hippel    O
(    O
1867–1939    O
)    O
,    O
a    O
German    O
ophthalmologist    O
,    O
his    O
son    O
(    O
discoverer    O
of    O
Von    B-Malignancy114237561
Hippel-Lindau    I-Malignancy114237561
disease    I-Malignancy114237561
)    O

Glial    O
tumor    O
is    O
a    O
general    O
term    O
for    O
numerous    O
tumors    O
of    O
the    O
central    O
nervous    O
system    O
,    O
including    O
astrocytomas    O
,    O
ependymal    O
tumors    O
,    O
glioblastoma    O
multiforme    O
,    O
and    O
primitive    B-Malignancy114237561
neuroectodermal    I-Malignancy114237561
tumor    I-Malignancy114237561
.    O

primitive    B-Malignancy114237561
neuroectodermal    I-Malignancy114237561
tumor    I-Malignancy114237561

The    O
Ewing    O
family    O
of    O
tumors    O
is    O
a    O
group    O
of    O
cancers    O
that    O
includes    O
Ewing    O
tumor    O
of    O
bone    O
(    O
ETB    O
or    O
Ewing    O
sarcoma    O
of    O
bone    O
)    O
,    O
extraosseous    O
Ewing    O
tumors    O
(    O
EOE    O
tumors    O
)    O
,    O
primitive    B-Malignancy114237561
neuroectodermal    I-Malignancy114237561
tumor    I-Malignancy114237561
(    O
PNET    O
or    O
peripheral    O
neuroepithelioma    O
)    O
,    O
and    O
Askin    O
tumors    O
(    O
PNET    O
of    O
the    O
chest    O
wall    O
)    O
.    O

In    O
rats    O
,    O
the    O
oncogenic    O
SV40    O
large    O
T    O
-    O
antigen    O
was    O
used    O
to    O
establish    O
a    O
brain    O
tumor    O
model    O
for    O
PNETs    B-Malignancy114237561
and    O
medulloblastomas    O
.    O

Considered    O
part    O
of    O
the    O
PTEN    O
hamartoma    O
tumor    O
syndrome    O
(    O
PHTS    O
)    O
,    O
which    O
also    O
includes    O
Bannayan-Riley-Ruvalcaba    B-Malignancy114237561
syndrome    I-Malignancy114237561
,    O
Proteus    O
syndrome    O
,    O
and    O
Proteus    O
-    O
like    O
syndrome    O
,    O
Cowden    B-Malignancy114237561
syndrome    I-Malignancy114237561
is    O
a    O
serious    O
genetic    O
disorder    O
characterized    O
by    O
multiple    O
hamartomas    O
.    O

"    O
PTEN    O
"    O
:    O
Mutations    O
cause    O
Cowden    B-Malignancy114237561
syndrome    I-Malignancy114237561
,    O
which    O
produces    O
hamartomas    O
(    O
benign    O
polyps    O
)    O
in    O
the    O
colon    O
,    O
skin    O
growths    O
,    O
and    O
other    O
clinical    O
signs    O
,    O
as    O
well    O
as    O
an    O
increased    O
risk    O
for    O
many    O
cancers    O
.    O

BMPR1A    O
,    O
SMAD4    O
and    O
PTEN    O
are    O
responsible    O
for    O
juvenile    B-Malignancy114237561
polyposis    I-Malignancy114237561
syndrome    I-Malignancy114237561
,    O
juvenile    O
intestinal    O
polyposis    O
and    O
Cowden's    B-Malignancy114237561
disease    I-Malignancy114237561
.    O

At    O
least    O
five    O
variants    O
in    O
the    O
SDHD    O
gene    O
have    O
been    O
identified    O
in    O
people    O
with    O
Cowden    B-Malignancy114237561
syndrome    I-Malignancy114237561
or    O
a    O
similar    O
disorder    O
called    O
Cowden    O
-    O
like    O
syndrome    O
.    O

It    O
is    O
often    O
associated    O
with    O
Cowden    B-Malignancy114237561
syndrome    I-Malignancy114237561
.    O

Induced    O
pluripotent    O
stem    O
cells    O
are    O
similar    O
to    O
natural    O
pluripotent    O
stem    O
cells    O
,    O
such    O
as    O
embryonic    O
stem    O
(    O
ES    O
)    O
cells    O
,    O
in    O
many    O
aspects    O
,    O
such    O
as    O
the    O
expression    O
of    O
certain    O
stem    O
cell    O
genes    O
and    O
proteins    O
,    O
chromatin    O
methylation    O
patterns    O
,    O
doubling    O
time    O
,    O
embryoid    O
body    O
formation    O
,    O
teratoma    B-Malignancy114237561
formation    O
,    O
viable    O
chimera    O
formation    O
,    O
and    O
potency    O
and    O
differentiability    O
,    O
but    O
the    O
full    O
extent    O
of    O
their    O
relation    O
to    O
natural    O
pluripotent    O
stem    O
cells    O
is    O
still    O
being    O
assessed    O
.    O

Teratoma    O
formation    O
:    O
iPSCs    O
injected    O
into    O
immunodeficient    O
mice    O
spontaneously    O
formed    O
teratoma    B-Malignancy114237561
after    O
nine    O
weeks    O
.    O

Much    O
the    O
same    O
as    O
ESC    O
,    O
iPSCs    O
readily    O
form    O
teratoma    B-Malignancy114237561
when    O
injected    O
into    O
immunodeficient    O
mice    O
.    O

When    O
a    O
similar    O
procedure    O
was    O
performed    O
on    O
genetically    O
equivalent    O
ES    O
cells    O
however    O
,    O
Zhou    O
et    O
al    O
.    O
found    O
teratoma    B-Malignancy114237561
,    O
which    O
indicated    O
that    O
the    O
cells    O
were    O
tolerated    O
by    O
the    O
immune    O
system    O
.    O

Teratoma    B-Malignancy114237561

Causes    O
of    O
meningocele    O
include    O
teratoma    B-Malignancy114237561
and    O
other    O
tumors    O
of    O
the    O
sacrococcyx    B-Malignancy114237561
and    O
of    O
the    O
presacral    O
space    O
,    O
and    O
Currarino    O
syndrome    O
.    O

A    O
struma    O
ovarii    O
(    O
literally    O
:    O
goitre    O
of    O
the    O
ovary    O
)    O
is    O
a    O
rare    O
form    O
of    O
monodermal    O
teratoma    B-Malignancy114237561
that    O
contains    O
mostly    O
thyroid    O
tissue    O
,    O
which    O
may    O
cause    O
hyperthyroidism    O
.    O

Teratoma    B-Malignancy114237561

Limbal    B-Malignancy114237561
dermoid    I-Malignancy114237561
,    O
a    O
kind    O
of    O
choristoma    O
(    O
NB    O
:    O
in    O
other    O
organs    O
"    O
dermoid    O
"    O
can    O
refer    O
to    O
a    O
teratoma    B-Malignancy114237561
)    O

It    O
has    O
been    O
found    O
for    O
induced    O
pluripotent    O
stem    O
cells    O
that    O
when    O
injected    O
into    O
mice    O
,    O
the    O
immune    O
system    O
of    O
the    O
synergeic    O
mouse    O
rejected    O
the    O
teratomas    B-Malignancy114237561
forming    O
.    O

It    O
is    O
not    O
a    O
teratoma    B-Malignancy114237561
,    O
however    O
,    O
which    O
is    O
a    O
neoplasm    O
comprising    O
all    O
three    O
germ    O
cell    O
layers    O
(    O
ectoderm    O
,    O
endoderm    O
,    O
mesoderm    O
)    O
.    O

With    O
the    O
advent    O
of    O
the    O
field    O
of    O
stem    O
cell    O
biology    O
,    O
the    O
potential    O
of    O
stem    O
cells    O
in    O
to    O
form    O
organs    O
"    O
in    O
vitro    O
"    O
was    O
realized    O
early    O
on    O
with    O
the    O
observation    O
that    O
when    O
stem    O
cells    O
form    O
teratoma    B-Malignancy114237561
or    O
embryoid    O
body    O
,    O
the    O
differentiated    O
cells    O
can    O
organize    O
into    O
different    O
structures    O
resembling    O
those    O
found    O
in    O
multiple    O
tissue    O
types    O
.    O

Jones    O
was    O
diagnosed    O
with    O
inoperable    O
brain    O
cancer    O
(    O
a    O
teratoma    B-Malignancy114237561
)    O
in    O
August    O
2005    O
and    O
fought    O
the    O
disease    O
for    O
nearly    O
three    O
years    O
,    O
dying    O
on    O
June    O
10    O
,    O
2008    O
at    O
the    O
age    O
of    O
46    O
.    O

Other    O
less    O
common    O
liver    O
cancers    O
include    O
carcinosarcomas    O
,    O
teratoma    B-Malignancy114237561
,    O
yolk    B-Malignancy114237561
sac    I-Malignancy114237561
tumour    I-Malignancy114237561
,    O
carcinoid    O
tumours    O
and    O
lymphomas    O
.    O

Paraneoplastic    B-Malignancy114237561
SPS    O
tends    O
to    O
affect    O
the    O
neck    O
and    O
arms    O
more    O
than    O
other    O
variations    O
.    O

Cancers    O
or    O
malignancies    O
such    O
as    O
leukemia    O
may    O
cause    O
increased    O
risk    O
of    O
thrombosis    O
by    O
possible    O
activation    O
of    O
the    O
coagulation    O
system    O
by    O
cancer    O
cells    O
or    O
secretion    O
of    O
procoagulant    O
substances    O
(    O
paraneoplastic    B-Malignancy114237561
syndrome    I-Malignancy114237561
)    O
,    O
by    O
external    O
compression    O
on    O
a    O
blood    O
vessel    O
when    O
a    O
solid    O
tumor    O
is    O
present    O
,    O
or    O
(    O
more    O
rarely    O
)    O
extension    O
into    O
the    O
vasculature    O
(    O
for    O
example    O
,    O
renal    O
cell    O
cancers    O
extending    O
into    O
the    O
renal    O
veins    O
)    O
.    O

Rarely    O
,    O
a    O
paraneoplastic    B-Malignancy114237561
syndrome    I-Malignancy114237561
of    O
osteoarthropathy    O
(    O
diseases    O
of    O
joints    O
and    O
bones    O
)    O
may    O
occur    O
with    O
widespread    O
disease    O
.    O

Bernatz    O
rapidly    O
acquired    O
clinical    O
experience    O
with    O
the    O
treatment    O
of    O
thymoma    B-Malignancy114237561
,    O
a    O
potentially    O
-    O
aggressive    O
mediastinal    O
neoplasm    O
which    O
can    O
be    O
associated    O
with    O
myasthenia    O
gravis    O
and    O
other    O
paraneoplastic    B-Malignancy114237561
syndrome    I-Malignancy114237561
.    O

Rare    O
but    O
characteristic    O
presentations    O
include    O
transverse    O
myelopathy    O
(    O
tumor    O
spinal    O
cord    O
compression    O
,    O
5%    O
of    O
cases    O
)    O
,    O
treatment    O
-    O
resistant    O
diarrhea    O
(    O
tumor    O
vasoactive    O
intestinal    O
peptide    O
secretion    O
,    O
4%    O
of    O
cases    O
)    O
,    O
Horner    O
's    O
syndrome    O
(    O
cervical    O
tumor    O
,    O
2.4%    O
of    O
cases    O
)    O
,    O
opsoclonus    O
myoclonus    O
syndrome    O
and    O
ataxia    O
(    O
suspected    O
paraneoplastic    B-Malignancy114237561
cause    O
,    O
1.3%    O
of    O
cases    O
)    O
,    O
and    O
hypertension    O
(    O
catecholamine    O
secretion    O
or    O
renal    O
artery    O
compression    O
,    O
1.3%    O
of    O
cases    O
)    O
.    O

Paraneoplastic    B-Malignancy114237561
neuromyopathy    O
and    O
neuropathy    O

Darnell    O
’s    O
early    O
research    O
was    O
concentrated    O
on    O
paraneoplastic    B-Malignancy114237561
syndrome    I-Malignancy114237561
(    O
PNDs    O
,    O
the    O
Paraneoplastic    O
Neurologic    O
Disorders    O
)    O
,    O
disorders    O
touching    O
on    O
various    O
clinical    O
and    O
basic    O
aspects    O
of    O
biology    O
including    O
Cancer    O
immunology    O
,    O
Neuroimmunology    O
.    O

Tumor    O
with    O
paraneoplastic    B-Malignancy114237561
syndrome    I-Malignancy114237561

Doege    O
-    O
Potter    O
syndrome    O
is    O
a    O
paraneoplastic    B-Malignancy114237561
syndrome    I-Malignancy114237561
in    O
which    O
hypoglycemia    O
is    O
associated    O
with    O
the    O
presence    O
of    O
one    O
or    O
more    O
non    O
-    O
islet    O
fibrous    O
tumors    O
in    O
the    O
pleural    O
cavity    O
.    O

In    O
the    O
episode    O
of    O
"    O
House    O
"    O
,    O
"    O
Skin    O
Deep    O
"    O
,    O
opioid    O
antagonist    O
drugs    O
were    O
administered    O
in    O
order    O
to    O
completely    O
remove    O
the    O
patient    O
's    O
heroin    O
induced    O
addiction    O
/    O
withdrawal    O
symptoms    O
(    O
during    O
an    O
induced    O
coma    O
in    O
order    O
to    O
relieve    O
the    O
extreme    O
pain    O
of    O
their    O
use    O
)    O
,    O
so    O
that    O
an    O
accurate    O
diagnosis    O
of    O
paraneoplastic    B-Malignancy114237561
syndrome    I-Malignancy114237561
caused    O
by    O
cancer    O
was    O
differentiated    O
.    O

PTEN    O
hamartoma    O
syndrome    O
comprises    O
four    O
distinct    O
hamartomatous    O
disorders    O
characterised    O
by    O
genetic    O
mutations    O
in    O
the    O
PTEN    O
gene    O
;    O
Cowden    B-Malignancy114237561
syndrome    I-Malignancy114237561
,    O
Bannayan-Riley-Ruvalcaba    B-Malignancy114237561
syndrome    I-Malignancy114237561
,    O
Proteus    O
syndrome    O
and    O
Proteus    O
-    O
like    O
syndrome    O
.    O

Considered    O
part    O
of    O
the    O
PTEN    O
hamartoma    O
tumor    O
syndrome    O
(    O
PHTS    O
)    O
,    O
which    O
also    O
includes    O
Bannayan-Riley-Ruvalcaba    B-Malignancy114237561
syndrome    I-Malignancy114237561
,    O
Proteus    O
syndrome    O
,    O
and    O
Proteus    O
-    O
like    O
syndrome    O
,    O
Cowden    B-Malignancy114237561
syndrome    I-Malignancy114237561
is    O
a    O
serious    O
genetic    O
disorder    O
characterized    O
by    O
multiple    O
hamartomas    O
.    O

Related    O
polyposis    O
conditions    O
are    O
familial    B-Malignancy114237561
adenomatous    I-Malignancy114237561
polyposis    I-Malignancy114237561
,    O
attenuated    B-Malignancy114237561
familial    I-Malignancy114237561
adenomatous    I-Malignancy114237561
polyposis    I-Malignancy114237561
,    O
Birt    O
–    O
Hogg–    O

Hyalinizing    B-Malignancy114237561
clear    I-Malignancy114237561
cell    I-Malignancy114237561
carcinoma    I-Malignancy114237561

Endocrine    B-Malignancy114237561
tumor    I-Malignancy114237561
(    O
pheochromocytoma    O
,    O
carcinoid    O
)    O

Most    O
children    O
(    O
>    O
80%    O
)    O
with    O
BWS    O
do    O
not    O
develop    O
cancer    O
;    O
however    O
,    O
children    O
with    O
BWS    O
are    O
much    O
more    O
likely    O
(    O
~600    O
times    O
more    O
)    O
than    O
other    O
children    O
to    O
develop    O
certain    O
childhood    O
cancers    O
,    O
particularly    O
Wilms'    B-Malignancy114237561
tumor    I-Malignancy114237561
(    O
nephroblastoma    O
)    O
,    O
pancreatoblastoma    O
and    O
hepatoblastoma    B-Malignancy114237561
.    O

Bleeding    O
due    O
to    O
rupture    O
of    O
an    O
intra    O
-    O
abdominal    O
neoplasm    O
,    O
(    O
e.g.    O
,    O
Hepatoblastoma    B-Malignancy114237561
)    O

Another    O
type    O
of    O
cancer    O
formed    O
by    O
liver    O
cells    O
is    O
hepatoblastoma    B-Malignancy114237561
,    O
which    O
is    O
specifically    O
formed    O
by    O
immature    O
liver    O
cells    O
.    O

Smoldering    B-Malignancy114237561
multiple    I-Malignancy114237561
myeloma    I-Malignancy114237561

TCGA    O
Targeted    O
Tumors    O
:    O
lung    O
squamous    O
cell    O
carcinoma    O
,    O
kidney    O
papillary    O
carcinoma    O
,    O
clear    O
cell    O
kidney    O
carcinoma    O
,    O
breast    O
ductal    O
carcinoma    O
,    O
renal    O
cell    O
carcinoma    O
,    O
cervical    O
cancer    O
(    O
squamous    O
)    O
,    O
colon    O
adenocarcinoma    O
,    O
stomach    O
adenocarcinoma    O
,    O
rectal    O
carcinoma    O
,    O
hepatocellular    O
carcinoma    O
,    O
Head    O
and    O
neck    O
(    O
oral    O
)    O
squamous    O
cell    O
carcinoma    O
,    O
thyroid    O
carcinoma    O
,    O
bladder    O
urothelial    O
carcinoma    O
-    O
nonpapillary    O
,    O
uterine    O
corpus    O
(    O
endometrial    O
carcinoma    O
)    O
,    O
pancreatic    O
ductal    O
adenocarcinoma    O
,    O
acute    O
myeloid    O
leukemia    O
,    O
prostate    O
adenocarcinoma    O
,    O
lung    O
adenocarcinoma    O
,    O
cutaneous    O
melanoma    O
,    O
breast    O
lobular    O
carcinoma    O
and    O
lower    O
grade    O
glioma    O
,    O
esophageal    O
carcinoma    O
,    O
ovarian    O
serous    O
cystadenocarcinoma    O
,    O
lung    O
squamous    O
cell    O
carcinoma    O
,    O
adrenocortical    B-Malignancy114237561
carcinoma    I-Malignancy114237561
,    O
Diffuse    O
Large    O
B    O
-    O
cell    O
lymphoma    O
,    O
paraganglioma    O
&    O
pheochromocytoma    O
,    O
cholangiocarcinoma    B-Malignancy114237561
,    O
uterine    O
carcinosarcoma    O
,    O
uveal    O
melanoma    O
,    O
thymoma    B-Malignancy114237561
,    O
sarcoma    O
,    O
mesothelioma    O
,    O
and    O
testicular    O
germ    O
cell    O
cancer    O
.    O

Those    O
affected    O
often    O
have    O
a    O
large    O
thymus    O
gland    O
or    O
develop    O
a    O
thymoma    B-Malignancy114237561
.    O

As    O
thymoma    B-Malignancy114237561
are    O
seen    O
in    O
10%    O
of    O
all    O
people    O
with    O
the    O
MG    O
,    O
people    O
are    O
often    O
given    O
a    O
chest    O
X    O
-    O
ray    O
and    O
CT    O
scan    O
to    O
evaluate    O
their    O
need    O
for    O
surgical    O
removal    O
of    O
their    O
thymus    O
and    O
any    O
cancerous    O
tissue    O
that    O
may    O
be    O
present    O
.    O

This    O
often    O
remains    O
true    O
in    O
neoplastic    O
cells    O
from    O
these    O
populations    O
,    O
so    O
that    O
the    O
presence    O
of    O
CD1    O
antigens    O
can    O
be    O
used    O
in    O
diagnostic    O
immunohistochemistry    O
to    O
identify    O
some    O
thymoma    B-Malignancy114237561
and    O
malignancies    O
arising    O
from    O
T    O
cell    O
precursors    O
.    O

It    O
can    O
also    O
serve    O
as    O
a    O
marker    O
of    O
basal    O
cell    O
carcinoma    O
,    O
transitional    O
cell    O
carcinoma    O
,    O
salivary    O
gland    O
tumors    O
,    O
and    O
thymoma    B-Malignancy114237561
.    O

Thymectomy    O
is    O
indicated    O
when    O
thymoma    B-Malignancy114237561
are    O
present    O
in    O
the    O
thymus    O
.    O

Collecting    B-Malignancy114237561
duct    I-Malignancy114237561
carcinoma    I-Malignancy114237561

Carcinoma    B-Malignancy114237561
of    I-Malignancy114237561
the    I-Malignancy114237561
penis    I-Malignancy114237561
is    O
rare    O
with    O
a    O
reported    O
rate    O
of    O
1    O
person    O
in    O
100,000    O
in    O
developed    O
countries    O
.    O

Orchid    O
is    O
a    O
British    O
charity    O
which    O
funds    O
research    O
into    O
the    O
diagnosis    O
,    O
prevention    O
and    O
treatment    O
of    O
prostate    O
,    O
penile    B-Malignancy114237561
and    O
testicular    O
cancer    O
.    O

Carcinoma    B-Malignancy114237561
of    I-Malignancy114237561
the    I-Malignancy114237561
penis    I-Malignancy114237561
ICD-10    O
code    O

Papillomaviruses    O
have    O
been    O
associated    O
with    O
the    O
development    O
of    O
cervical    O
cancer    O
,    O
penile    B-Malignancy114237561
cancer    I-Malignancy114237561
and    O
oral    O
cancers    O
.    O

Malignant    B-Malignancy114237561
acrospiroma    I-Malignancy114237561

Hypopharyngeal    B-Malignancy114237561
cancer    I-Malignancy114237561

Tumor    O
types    O
include    O
Sertoli    B-Malignancy114237561
cell    I-Malignancy114237561
tumor    I-Malignancy114237561
,    O
seminoma    O
,    O
and    O
interstitial    B-Malignancy114237561
cell    I-Malignancy114237561
tumor    I-Malignancy114237561
.    O

Testicular    O
cancer    O
,    O
Leydig    B-Malignancy114237561
cell    I-Malignancy114237561
tumour    I-Malignancy114237561
and    O
Sertoli    B-Malignancy114237561
cell    I-Malignancy114237561
tumour    I-Malignancy114237561
are    O
also    O
associated    O
with    O
reduced    O
sperm    O
count    O
and    O
quality    O
.    O

OSLAM    B-Malignancy114237561
syndrome    I-Malignancy114237561
is    O
a    O
rare    O
autosomal    O
dominant    O
hereditary    O
disorder    O
.    O

Juxtaglomerular    B-Malignancy114237561
cell    I-Malignancy114237561
tumor    I-Malignancy114237561

renal    O
cancer    O
is    O
part    O
of    O
a    O
rare    O
,    O
genetic    O
disorder    O
known    O
as    O
Birt-Hogg-Dubé    B-Malignancy114237561
syndrome    I-Malignancy114237561
.    O

Birt-Hogg-Dubé    B-Malignancy114237561
syndrome    I-Malignancy114237561

Hepatosplenic    B-Malignancy114237561
T-cell    I-Malignancy114237561
lymphoma    I-Malignancy114237561
is    O
a    O
rare    O
and    O
generally    O
incurable    O
form    O
of    O
lymphoma    O
.    O

TCGA    O
Targeted    O
Tumors    O
:    O
lung    O
squamous    O
cell    O
carcinoma    O
,    O
kidney    O
papillary    O
carcinoma    O
,    O
clear    O
cell    O
kidney    O
carcinoma    O
,    O
breast    O
ductal    O
carcinoma    O
,    O
renal    O
cell    O
carcinoma    O
,    O
cervical    O
cancer    O
(    O
squamous    O
)    O
,    O
colon    O
adenocarcinoma    O
,    O
stomach    O
adenocarcinoma    O
,    O
rectal    O
carcinoma    O
,    O
hepatocellular    O
carcinoma    O
,    O
Head    O
and    O
neck    O
(    O
oral    O
)    O
squamous    O
cell    O
carcinoma    O
,    O
thyroid    O
carcinoma    O
,    O
bladder    O
urothelial    O
carcinoma    O
-    O
nonpapillary    O
,    O
uterine    O
corpus    O
(    O
endometrial    O
carcinoma    O
)    O
,    O
pancreatic    O
ductal    O
adenocarcinoma    O
,    O
acute    O
myeloid    O
leukemia    O
,    O
prostate    O
adenocarcinoma    O
,    O
lung    O
adenocarcinoma    O
,    O
cutaneous    O
melanoma    O
,    O
breast    O
lobular    O
carcinoma    O
and    O
lower    O
grade    O
glioma    O
,    O
esophageal    O
carcinoma    O
,    O
ovarian    O
serous    O
cystadenocarcinoma    O
,    O
lung    O
squamous    O
cell    O
carcinoma    O
,    O
adrenocortical    B-Malignancy114237561
carcinoma    I-Malignancy114237561
,    O
Diffuse    O
Large    O
B    O
-    O
cell    O
lymphoma    O
,    O
paraganglioma    O
&    O
pheochromocytoma    O
,    O
cholangiocarcinoma    B-Malignancy114237561
,    O
uterine    O
carcinosarcoma    O
,    O
uveal    O
melanoma    O
,    O
thymoma    B-Malignancy114237561
,    O
sarcoma    O
,    O
mesothelioma    O
,    O
and    O
testicular    O
germ    O
cell    O
cancer    O
.    O

A    O
Klatskin    O
tumor    O
(    O
or    O
hilar    O
cholangiocarcinoma    O
)    O
is    O
a    O
cholangiocarcinoma    B-Malignancy114237561
(    O
cancer    O
of    O
the    O
biliary    O
tree    O
)    O
occurring    O
at    O
the    O
confluence    O
of    O
the    O
right    O
and    O
left    O
hepatic    O
bile    O
ducts    O
.    O

cholangiocarcinoma    B-Malignancy114237561

Mir-22    O
was    O
found    O
to    O
be    O
over    O
-    O
expressed    O
in    O
prostate    O
cancer    O
but    O
down    O
-    O
regulated    O
in    O
breast    O
cancer    O
,    O
cholangiocarcinoma    B-Malignancy114237561
,    O
multiple    O
myeloma    O
and    O
hepatocellular    O
carcinoma    O
.    O

On    O
November    O
21    O
,    O
2013    O
,    O
Kavli    O
died    O
at    O
his    O
Santa    O
Barbara    O
,    O
California    O
home    O
after    O
surgery    O
for    O
cholangiocarcinoma    B-Malignancy114237561
,    O
a    O
rare    O
form    O
of    O
cancer    O
.    O

Jaundice    O
is    O
commonly    O
caused    O
by    O
conditions    O
such    O
as    O
pancreatic    O
cancer    O
,    O
which    O
causes    O
blockage    O
of    O
the    O
bile    O
duct    O
passing    O
through    O
the    O
cancerous    O
portion    O
of    O
the    O
pancreas    O
;    O
cholangiocarcinoma    B-Malignancy114237561
,    O
cancer    O
of    O
the    O
bile    O
ducts    O
;    O
blockage    O
by    O
a    O
stone    O
in    O
patients    O
with    O
gallstones    O
;    O
and    O
from    O
scarring    O
after    O
injury    O
to    O
the    O
bile    O
duct    O
during    O
gallbladder    O
removal    O
.    O

Cholangiocarcinoma    B-Malignancy114237561
or    O
bile    O
duct    O
cancer    O
is    O
a    O
form    O
of    O
cancer    O
that    O
is    O
composed    O
of    O
mutated    O
epithelial    O
cells    O
(    O
or    O
cells    O
showing    O
characteristics    O
of    O
epithelial    O
differentiation    O
)    O
that    O
originate    O
in    O
the    O
bile    O
ducts    O
.    O

10–30%    O
of    O
cases    O
,    O
however    O
,    O
are    O
due    O
to    O
other    O
causes    O
such    O
as    O
benign    O
stricturing    O
(    O
narrowing    O
of    O
the    O
bile    O
duct    O
without    O
an    O
underlying    O
tumor    O
)    O
,    O
postoperative    O
damage    O
or    O
an    O
altered    O
structure    O
of    O
the    O
bile    O
ducts    O
such    O
as    O
narrowing    O
at    O
the    O
site    O
of    O
an    O
anastomosis    O
(    O
surgical    O
connection    O
)    O
,    O
various    O
tumors    O
(    O
cancer    B-Malignancy114237561
of    I-Malignancy114237561
the    I-Malignancy114237561
bile    I-Malignancy114237561
duct    I-Malignancy114237561
,    O
gallbladder    O
cancer    O
,    O
cancer    O
of    O
the    O
ampulla    O
of    O
Vater    O
,    O
pancreatic    O
cancer    O
,    O
cancer    O
of    O
the    O
duodenum    O
)    O
,    O
anaerobic    O
organisms    O
such    O
as    O
Clostridium    O
and    O
Bacteroides    O
(    O
especially    O
in    O
the    O
elderly    O
and    O
those    O
who    O
have    O
undergone    O
previous    O
surgery    O
of    O
the    O
biliary    O
system    O
)    O
.    O

He    O
died    O
of    O
cholangiocarcinoma    B-Malignancy114237561
(    O
bile    O
duct    O
cancer    O
)    O
in    O
Lymington    O
,    O
Hampshire    O
.    O

He    O
had    O
received    O
hospice    O
care    O
following    O
unsuccessful    O
treatment    O
for    O
bile    B-Malignancy114237561
duct    I-Malignancy114237561
cancer    I-Malignancy114237561
.    O

November    O
18    O
-    O
Peter    O
Wintonick    O
,    O
60    O
,    O
documentary    O
filmmaker    O
,    O
cholangiocarcinoma    B-Malignancy114237561
(    O
born    O
1953    O
)    O
.    O

The    O
most    O
common    O
types    O
are    O
hepatocellular    O
carcinoma    O
(    O
HCC    O
)    O
,    O
which    O
makes    O
up    O
80%    O
of    O
cases    O
,    O
and    O
cholangiocarcinoma    B-Malignancy114237561
.    O

Cancer    O
of    O
the    O
bile    O
duct    O
(    O
cholangiocarcinoma    B-Malignancy114237561
and    O
cholangiocellular    O
cystadenocarcinoma    O
)    O
account    O
for    O
approximately    O
6%    O
of    O
primary    O
liver    O
cancers    O
.    O

HBV    O
infection    O
is    O
also    O
linked    O
to    O
cholangiocarcinoma    B-Malignancy114237561
.    O

:    O
Ganglioneuroma    O
,    O
Neuroblastoma    O
,    O
Atypical    B-Malignancy114237561
teratoid    I-Malignancy114237561
rhabdoid    I-Malignancy114237561
tumor    I-Malignancy114237561
,    O
Retinoblastoma    O
,    O
Esthesioneuroblastoma    B-Malignancy114237561

Correct    O
diagnosis    O
of    O
medulloblastoma    O
may    O
require    O
ruling    O
out    O
atypical    B-Malignancy114237561
teratoid    I-Malignancy114237561
rhabdoid    I-Malignancy114237561
tumor    I-Malignancy114237561
(    O
ATRT    O
)    O

Urethral    B-Malignancy114237561
cancer    I-Malignancy114237561

Three    O
seasons    O
later    O
,    O
Esterhaus    O
dies    O
during    O
a    O
romantic    O
tryst    O
with    O
Grace    O
Gardner    O
;    O
this    O
served    O
to    O
cover    O
for    O
Michael    O
Conrad    O
's    O
death    O
due    O
to    O
urethral    B-Malignancy114237561
cancer    I-Malignancy114237561
on    O
November    O
22    O
,    O
1983    O
.    O

Although    O
these    O
are    O
the    O
same    O
genes    O
mutated    O
in    O
the    O
condition    O
known    O
as    O
Lynch    B-Malignancy114237561
syndrome    I-Malignancy114237561
or    O
hereditary    B-Malignancy114237561
nonpolyposis    I-Malignancy114237561
colorectal    I-Malignancy114237561
cancer    I-Malignancy114237561
,    O
the    O
mutations    O
are    O
biallelic    O
in    O
CMMR    O
-    O
D.    O

Alternatively    O
,    O
elevated    O
IEL    O
populations    O
can    O
be    O
a    O
marker    O
for    O
developing    O
neoplasia    O
in    O
the    O
tissue    O
such    O
as    O
found    O
in    O
cervical    O
and    O
prostate    O
cancers    O
,    O
as    O
well    O
as    O
some    O
colorectal    O
cancers    O
,    O
particularly    O
those    O
associated    O
with    O
Lynch    B-Malignancy114237561
syndrome    I-Malignancy114237561
(    O
hereditary    O
non    O
-    O
polyposis    O
colon    O
cancer    O
)    O
.    O

Jeghers    O
syndrome    O
due    O
to    O
mutations    O
in    O
the    O
"    O
STK11    O
"    O
tumor    O
suppressor    O
gene    O
(    O
very    O
rare    O
,    O
but    O
a    O
very    O
strong    O
risk    O
factor    O
)    O
;    O
dysplastic    O
nevus    O
syndrome    O
(    O
or    O
familial    O
atypical    O
multiple    O
mole    O
and    O
melanoma    O
syndrome    O
,    O
FAMMM    O
-    O
PC    O
)    O
due    O
to    O
mutations    O
in    O
the    O
"    O
CDKN2A    O
"    O
tumor    O
suppressor    O
gene    O
;    O
autosomal    O
recessive    O
ataxia    O
-    O
telangiectasia    O
and    O
autosomal    O
dominantly    O
inherited    O
mutations    O
in    O
the    O
"    O
BRCA2    O
"    O
gene    O
and    O
"    O
PALB2    O
"    O
gene    O
;    O
hereditary    B-Malignancy114237561
non-polyposis    I-Malignancy114237561
colon    I-Malignancy114237561
cancer    I-Malignancy114237561
(    O
Lynch    O
syndrome    O
)    O
;    O
and    O
familial    B-Malignancy114237561
adenomatous    I-Malignancy114237561
polyposis    I-Malignancy114237561
.    O

Lynch    B-Malignancy114237561
syndrome    I-Malignancy114237561
,    O
a    O
medical    O
condition    O

The    O
main    O
hereditary    O
predispositions    O
are    O
mainly    O
neurofibromatosis    O
type    O
I    O
,    O
Li-Fraumeni    B-Malignancy114237561
syndrome    I-Malignancy114237561
,    O
hereditary    B-Malignancy114237561
nonpolyposis    I-Malignancy114237561
colorectal    I-Malignancy114237561
cancer    I-Malignancy114237561
and    O
tuberous    O
sclerosis    O
.    O

Inactivation    O
of    O
DNA    O
Mismatch    O
Repair    O
(    O
MMR    O
)    O
as    O
identified    O
by    O
elevation    O
of    O
mutation    O
rates    O
is    O
the    O
cause    O
of    O
Lynch    B-Malignancy114237561
Syndrome    I-Malignancy114237561
(    O
LS    O
)    O
,    O
also    O
known    O
as    O
hereditary    O
nonpolyposis    O
colorectal    O
cancer    O
(    O
HNPCC    O
)    O
,    O
down    O
-    O
regulation    O
of    O
MMR    O
controlling    O
protein    O
is    O
carried    O
out    O
by    O
over    O
-    O
expression    O
of    O
miR-155    O
,    O
MMR    O
is    O
controlled    O
by    O
a    O
group    O
of    O
conserved    O
proteins    O
,    O
reduced    O
activity    O
of    O
these    O
proteins    O
results    O
in    O
elevated    O
levels    O
of    O
mutations    O
in    O
the    O
phenotype    O
triggering    O
a    O
march    O
towards    O
developing    O
this    O
type    O
of    O
cancer    O
.    O

Colorectal    O
cancer    O
due    O
to    O
hereditary    B-Malignancy114237561
nonpolyposis    I-Malignancy114237561
colorectal    I-Malignancy114237561
cancer    I-Malignancy114237561

His    O
best    O
-    O
known    O
example    O
,    O
hereditary    O
nonpolyposis    O
colorectal    O
cancer    O
,    O
is    O
the    O
most    O
common    O
form    O
of    O
hereditary    O
colorectal    O
cancer    O
and    O
is    O
generally    O
known    O
as    O
Lynch    B-Malignancy114237561
syndrome    I-Malignancy114237561
.    O

He    O
is    O
a    O
co    O
-    O
author    O
of    O
the    O
Bethesda    O
Guidelines    O
for    O
the    O
diagnosis    O
of    O
Hereditary    B-Malignancy114237561
non-polyposis    I-Malignancy114237561
colorectal    I-Malignancy114237561
cancer    I-Malignancy114237561
(    O
HNPCC    O
)    O
.    O

Epithelial-myoepithelial    B-Malignancy114237561
carcinoma    I-Malignancy114237561
of    I-Malignancy114237561
the    I-Malignancy114237561
lung    I-Malignancy114237561

It    O
is    O
usually    O
used    O
in    O
the    O
description    O
of    O
desmoplastic    B-Malignancy114237561
small    I-Malignancy114237561
round    I-Malignancy114237561
cell    I-Malignancy114237561
tumor    I-Malignancy114237561
.    O

Desmoplastic    B-Malignancy114237561
small-round-cell    I-Malignancy114237561
tumor    I-Malignancy114237561
-    O
A    O
rare    O
cancer    O
that    O
has    O
no    O
standardised    O
treatment    O
or    O
cure    O
.    O

A    O
mastocytoma    O
or    O
mast    O
cell    O
tumor    O
is    O
a    O
type    O
of    O
round-cell    B-Malignancy114237561
tumor    I-Malignancy114237561
consisting    O
of    O
mast    O
cells    O
.    O

Adamantinoma    B-Malignancy114237561
(    O
from    O
the    O
Greek    O
word    O
"    O
adamantinos    O
"    O
,    O
meaning    O
"    O
very    O
hard    O
"    O
)    O
is    O
a    O
rare    O
bone    O
cancer    O
,    O
making    O
up    O
less    O
than    O
1%    O
of    O
all    O
bone    O
cancers    O
.    O


